



ANTICANCER DRUGS SOURCED FROM MARINE LIFE

**Ramasamy Santhanam
Santhanam Ramesh
Subbiah Balasundari
Sheba David**

Bentham Books

Medicinal Chemistry and Marine Life

(Volume 1)

Anticancer Drugs Sourced from Marine Life

Authored by

Ramasamy Santhanam

*Fisheries College and Research Institute
Tamil Nadu Veterinary and Animal Sciences University
Thoothukudi-628008
India*

Santhanam Ramesh

*Karuna College of Pharmacy
Kerala University of Health Sciences
Thirumittacode, Palakkad 679 533, Kerala
India*

Subbiah Balasundari

*Dr.M.G.R. Fisheries College and Research Institute
Tamil Nadu Fisheries University, Thalainayeru
Tamil Nadu-614712
India*

&

Sheba R. David

*School of Pharmacy, University of Wyoming, Laramie
Wyoming 82071-3375
USA*

O g l e p c n E j g o k m { ' c p f ' O c t k p g ' N h g

(Volume 1)

Anticancer Drugs Sourced from Marine Life

Authors: Ramasamy Santhanam, Santhanam Ramesh, Subbiah Balasundari

& Sheba R. David

ISBN (Online): 978-981-5256-05-5

ISBN (Print): 978-981-5256-06-2

ISBN (Paperback): 978-981-5256-07-9

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
CHAPTER 1 INTRODUCTION	1
INTRODUCTION	1
Approved Drugs Sourced from Marine Biota	1
Cancer as a Major Public Health Problem	2
Pathophysiology of Cancer	3
Anticancer Potential of Marine Organisms	3
Most Promising Marine Biota-Derived Anticancer Compounds for the Different Types of Human Cancer	4
<i>Human Colon Cancer</i>	4
<i>Human Cervical Cancer</i>	4
<i>Blood Cancer</i>	4
<i>Mammary Cancer</i>	5
<i>Hepatic Cancer</i>	5
<i>Human Skin Cancer</i>	5
Biogeography of Marine Invertebrate Species Yielding Anticancer Compounds	5
Major Constraints in the Development of Anticancer Drugs	7
CONCLUSION	7
CHAPTER 2 MARINE BIO-CHEMICAL DIVERSITY: PROMISING ANTICANCER GROUPS	8
INTRODUCTION	8
Promising Anticancer Marine Biodiversity	9
<i>Marine Microalgae</i>	9
<i>Macroalgae (Seaweeds)</i>	9
<i>Mangrove Plants</i>	10
<i>Marine Invertebrates</i>	10
Promising Anticancer Marine Biota-derived Chemical Diversity	14
Predicted Total Number of Secondary Metabolites in Marine Plants and Invertebrates	15
Anticancer Marine Chemical Classes	15
<i>Polyphenols</i>	16
<i>Polysaccharides</i>	16
<i>Alkaloids</i>	16
<i>Peptides</i>	16
<i>Antibiotics</i>	17
Anticancer Chemical Diversity of Marine Biota	17
CONCLUSION	19
CHAPTER 3 MARINE BIOTA-BASED ANTICANCER DRUG CANDIDATES IN PIPELINE	20
INTRODUCTION	20
APPROVED AND MARKETED ANTICANCER DRUGS DERIVED FROM MARINE SPONGES	20
Eribulin Mesylate (E7389, Halaven®)	21
Panobinostat (LBH-589, Farydak®)	21
APPROVED AND MARKETED ANTICANCER DRUGS DERIVED FROM MARINE MOLLUSKS/CYANOBACTERIA ASSOCIATION	21
Brentuximab Vedotin ((SGN-35, Adcetris®)	22
Polatuzumab Vedotin	22

Enfortumab Vedotin-Eifv (Padcev®)	22
Disitamab Vedotin	22
Tisotumab Vedotin-tftv (Tivdak®)	22
Belantamab Mafodotin-blmf (Blenrep®)	22
APPROVED AND MARKETED ANTICANCER DRUGS DERIVED FROM MARINE	
TUNICATES	23
Plitidepsin (Aplidin®)	23
Trabectedin (Yondelis®)	23
Lurbinectedin	23
MARINE BIOTA- DERIVED ANTICANCER COMPOUNDS IN CLINICAL TRIALS	29
ANTICANCER MARINE SPECIES IN CLINICAL TRIALS	30
PATENTED NEW CHEMICAL ENTITIES (NCES) WITH ANTICANCER ACTIVITIES	
FROM MARINE BIOTA	41
Limiting Factors in the Development and Approval of Drugs from Marine Biota	44
Significant Challenges in the Development and Approval of Marine Drugs	44
CONCLUSION	45
CHAPTER 4 ANTICANCER POTENTIAL OF MARINE PLANTS	46
INTRODUCTION	46
Microalgae	47
Green Algae	47
<i>Chlorella</i> sp.	47
<i>Dunaliella tertiolecta</i>	47
BLUE-GREEN ALGAE	48
<i>Anabaena</i> sp.	48
<i>Arthrospira platensis</i> (= <i>Spirulina platensis</i>)	48
<i>Calothrix</i> sp.	48
<i>Coleofasciculus</i> sp.	49
<i>Cyanobium</i> sp.	49
<i>Dapis</i> sp.	49
<i>Leptolyngbya halophila</i>	49
<i>Leptolyngbya mycoidea</i>	50
<i>Leptolyngbya fragilis</i>	50
<i>Leptolyngbya</i> sp.	50
<i>Leptothoe kymatousa</i> , <i>Leptothoe sithoniana</i> and <i>Leptothoe spongobia</i>	50
<i>Nodosilinea nodulosa</i>	51
<i>Lyngbya majuscula</i>	51
<i>Lyngbya polychroa</i>	52
<i>Lyngbya</i> sp.	53
<i>Microcystis aeruginosa</i>	53
<i>Moorea bouillonii</i> (= <i>Lyngbya boulloni</i>)	54
<i>Moorea producens</i>	55
<i>Nodularia spumigena</i>	59
<i>Nodularia</i> sp. LEGE 06071	59
<i>Nostoc commune</i>	59
<i>Nostoc linckia</i>	60
<i>Nostoc linckia</i> and <i>Nostoc spongioforme</i>	60
<i>Nostoc</i> sp.	60
<i>Nodosilinea nodulosa</i> LEGE 06102	61
<i>Okeania hirsuta</i>	61
<i>Okeania</i> sp.	62

<i>Phormidium</i> sp.	62
<i>Pseudanabaena curta</i>	63
<i>Pseudanabaena</i> sp. LEGE 06144	63
<i>Romeria gracilis</i>	63
<i>Schizothrix calcicola</i>	63
<i>Schizothrix</i> sp.	64
<i>Symploca hydroides</i>	64
<i>Symploca</i> sp.	67
<i>Synechocystis salina</i>	70
<i>Synechocystis</i> sp. PCC 6803	70
<i>Synechococcus</i> sp.	70
Golden-brown, and Yellow Algae	70
<i>Isochrysis galbana</i>	70
<i>Prymnesium parvum</i>	71
Yellow-Green Algae (Diatoms)	72
<i>Chaetoceros simplex</i> var. <i>calcitrans</i> (= <i>Chaetoceros calcitrans</i>)	72
<i>Cocconeis scutellum</i>	72
<i>Cylindrotheca closterium</i>	72
<i>Haslea karadagensis</i>	72
<i>Navicula salinicola</i> (= <i>Navicula incerta</i>)	72
<i>Odontella aurita</i>	73
<i>Phaeodactylum tricornerutum</i>	73
<i>Pseudo-nitzschia delicatissima</i>	74
<i>Skeletonema costatum</i>	74
<i>Skeletonema marinoi</i>	74
<i>Synedra acus</i>	74
<i>Thalassionema nitzschioides</i>	75
<i>Thalassiosira rotula</i>	75
<i>Thalassiosira rotula</i> , <i>Skeletonema costatum</i> and <i>Pseudo-nitzschia delicatissima</i>	75
<i>Vibrio ostrearius</i> (= <i>Haslea ostrearia</i>)	75
Dinoflagellates	75
<i>Alexandrium andersoni</i>	75
<i>Alexandrium pseudogonyaulax</i> (= <i>Goniodoma pseudogoniaulax</i>) <i>Alexandrium</i> <i>monilatum</i> and <i>Alexandrium hiranoi</i>	76
<i>Alexandrium minutum</i>	76
<i>Alexandrium ostenfeldii</i>	76
<i>Alexandrium peruvianum</i>	78
<i>Amphidinium carterae</i>	78
<i>Amphidinium operculatum</i> AA60	79
<i>Amphidinium</i> sp. S1-36-5	79
<i>Amphidinium</i> sp. 12012-7-4A	80
<i>Amphidinium</i> sp. 1	80
<i>Amphidinium</i> sp. 2	80
<i>Amphidinium</i> sp. 3	80
<i>Amphidinium</i> sp. 5	81
<i>Amphidinium</i> sp. 7	81
<i>Alexandrium tamarense</i>	81
<i>Azadinium</i> sp.	81
<i>Cripthecodinium chonii</i>	82
<i>Dinophysis acuminata</i>	82
<i>Dinophysis acuta</i>	83

<i>Dinophysis caudata</i>	84
<i>Dinophysis fortii</i> , <i>Dinophysis miles</i> , <i>Dinophysis norvegica</i> , <i>Dinophysis rotundatum</i> and <i>Dinophysis sacculus</i>	84
<i>Dinophysis tripos</i>	84
<i>Gambierdiscus australes</i>	84
<i>Gambierdiscus pacificus</i> and <i>Gambierdiscus toxicus</i>	84
<i>Gambierdiscus toxicus</i>	85
<i>Gonyaulax spinifera</i>	85
<i>Heterocapsa circularisquama</i>	86
<i>Heterocapsa triquetra</i>	86
<i>Karlodinium veneficum</i>	86
<i>Karenia mikimotoi</i> (= <i>Gymnodinium mikimotoi</i>)	87
<i>Karenia selliformis</i> (= <i>Gymnodinium selliforme</i>)	87
<i>Ostreopsis factorussoi</i>	87
<i>Ostreopsis ovata</i>	87
<i>Ostreopsis siamensis</i>	88
<i>Phalacroma mitra</i> (= <i>Dinophysis mitra</i>) and <i>Phalacroma rotundatum</i> (= <i>Dinophysis</i> <i>rotundata</i>)	88
<i>Prorocentrum arenarium</i>	88
<i>Prorocentrum hoffmannianum</i> (= <i>Prorocentrum belezeanum</i> ; <i>Prorocentrum</i> <i>maculosum</i>)	89
<i>Prorocentrum concavum</i> and <i>Prorocentrum lima</i>	89
<i>Prorocentrum reticulatum</i>	89
<i>Symbiodinium</i> sp.	89
<i>Vulcanodinium rugosum</i>	90
Red alga	91
<i>Porphyridium cruentum</i> (= <i>Porphyridium purpureum</i>)	91
Macroalgae (Seaweeds)	91
Green algae	91
Brown algae	93
<i>Fucus vesiculosus</i> , <i>Laminaria japonica</i> , <i>Alaria esculenta</i> , <i>Ascophyllum nodosum</i> , <i>Bifurcaria bifurcata</i> and <i>Sargassum muticum</i> and <i>Bifurcaria bifurcata</i>	93
<i>Carpodesmia tamariscifolia</i> (= <i>Cystoseira tamariscifolia</i>)	93
<i>Colpomenia sinuosa</i> and <i>Sargassum prismaticum</i>	93
<i>Eisenia bicyclis</i>	94
<i>Ecklonia cava</i>	94
<i>Fucus vesiculosus</i>	94
<i>Ishige okamurae</i>	94
<i>Laminaria digitata</i>	95
<i>Laminaria japonica</i>	95
<i>Sargassum carpophyllum</i>	95
<i>Sargassum filipendula</i>	96
<i>Sargassum hemiphyllum</i>	96
<i>Sargassum</i> sp.	96
<i>Stypodium zonale</i>	96
<i>Undaria pinnatifida</i>	96
Red algae	97
<i>Amphiroa anceps</i>	97
<i>Champia feldmanni</i>	97
<i>Champia parvula</i>	97
<i>Chondrus armatus</i>	97

<i>Chondrus ocellatus</i>	98
Chondrus, Gigartina, Eucheuma and Iridaea sp.	98
<i>Cladosiphon okamrensis</i> and <i>Eucheuma cottonii</i>	98
<i>Eucheuma cottonii</i>	98
<i>Corallina mediterranea</i>	98
<i>Fucus vesiculosus</i>	99
<i>Gigartina pistillata</i>	99
<i>Gracilaria dominguensis</i>	99
<i>Grateloupia filicina</i>	99
<i>Laurencia papillosa</i>	99
Lophocladia sp.	99
<i>Palmaria palmata</i>	100
<i>Portieria hornemannii</i> and <i>Spyridia fustiformis</i>	100
Seagrasses	100
<i>Cymodocea serrulata</i>	100
<i>Halophila stipulaceae</i>	100
<i>Posidonia oceanica</i>	100
<i>Syringodium filiforme</i>	101
<i>Thalassia testudinum</i>	101
Mangroves	101
<i>Acanthus ilicifolius</i>	101
<i>Aegiceras corniculatum</i>	102
<i>Avicennia alba</i>	102
<i>Avicennia officinalis</i>	102
<i>Avicennia marina</i>	103
<i>Bruguiera cylindrica</i>	103
<i>Bruguiera gymnorrhiza</i>	104
<i>Bruguiera sexangular</i>	105
<i>Ceriops decandra</i>	105
<i>Ceriops tagal</i>	105
<i>Excoecaria agallocha</i>	106
<i>Heritiera fome</i>	107
<i>Heritiera littoralis</i>	107
<i>Ipomoea tuba</i>	107
<i>Nypa fruticans</i>	108
<i>Rhizophora apiculata</i>	108
<i>Rhizophora stylosa</i>	109
<i>Sonneratia apetala</i>	109
<i>Sonneratia caseolaris</i>	109
<i>Sonneratia paracaseolaris</i>	109
<i>Thalassodendron ciliatum</i>	110
<i>Xylocarpus granatum</i>	110
<i>Xylocarpus</i> sp.	111
Halophytes	111
<i>Salicornia europaea</i> (= <i>Salicornia herbacea</i>)	111
<i>Salicornia freitagii</i>	112
CONCLUSION	112
CHAPTER 5 ANTICANCER POTENTIAL OF MARINE SPONGES	113
INTRODUCTION	113
Anticancer Activity of Alkaloids of Marine Sponges	113

<i>Aaptos aaptos</i>	113
<i>Aaptos suberitoides</i>	114
<i>Aaptos</i> sp.	115
<i>Aplysina aerophoba</i>	115
<i>Arenosclera brasiliensis</i>	115
<i>Batzella</i> sp.	117
<i>Dragmacidon</i> sp.	117
<i>Ectenascidia turbinata</i>	117
<i>Fascaplysinopsis reticulata</i>	118
<i>Fascaplysinopsis</i> sp.	118
<i>Kirkpatrickia variolosa</i>	118
<i>Latrunculia (Latrunculia) brevis</i>	119
<i>Leucetta chagosensis</i>	119
<i>Monanchora arbuscula</i>	120
<i>Monanchora pulchra</i>	121
<i>Monanchora unguiculata</i>	122
<i>Oceanapia sagittaria</i>	123
<i>Pachychalina alcaloidifera</i>	123
<i>Pseudoceratina purpurea (= Dendrilla verongiformis)</i>	124
<i>Pseudoceratina</i> sp. (= <i>Psammoplysilla</i> sp.)	125
<i>Stylissa massa (= Hymeniacion aldís)</i>	126
<i>Xestospongia</i> sp. 1 and 2	127
<i>Zyzza fuliginosa</i>	127
Anticancer Activity of Terpenes of Marine Sponges	128
<i>Aka (Siphonodictio) corallifagum</i>	128
<i>Callyspongia (Callyspongia) siphonella (= Siphonochalina siphonella)</i>	128
<i>Dactylospongia elegans</i>	129
<i>Diacarnus megaspinorhabdosa</i>	129
<i>Dysidea villosa</i>	130
<i>Fasciospongia cavernosa</i>	130
<i>Geodia japonica</i>	130
<i>Haliclona</i> sp.	131
<i>Hyrtios erectus</i>	132
<i>Hyrtios reticulatus</i>	133
<i>Hyrtios</i> sp.	133
<i>Jaspis stellifera</i>	133
<i>Jaspis</i> sp.	134
<i>Niphates olemda</i>	134
<i>Psammocinia</i> sp.	135
<i>Phorbas gukhulensis</i>	135
<i>Rhabdastrella globostellata</i>	136
<i>Sarcotragus</i> sp. 1	136
<i>Sarcotragus</i> sp. 2	137
<i>Scalarispongia scalaris (= Cacospongia scalaris)</i>	137
<i>Siphonochalina</i> sp.	137
<i>Smenospongia aurea</i>	138
<i>Spongia</i> sp.	138
ANTICANCER ACTIVITY OF PEPTIDES OF MARINE SPONGES	138
<i>Amphibleptula</i> sp.	138
<i>Hemiasterella vasiformis</i> var. <i>minor</i> (= <i>Hemiasterella minor</i>)	138
<i>Geodia tylastra (= Geodia corticostylifera)</i>	139

<i>Hemiasrella minor</i>	139
<i>Lendenfeldia chondrodes</i> (= <i>Fasciospongia chondrodes</i>)	140
<i>Pachymatisma johnstonia</i>	140
<i>Smenospongia aurea</i>	140
<i>Stylissa</i> sp.	141
<i>Theonella swinhoei</i>	141
Anticancer Activity of Lipids of Marine Sponges	143
<i>Agelas mauritiana</i>	143
<i>Aplysilla glacialis</i>	143
<i>Axinella infundibuliformis</i>	143
<i>Dysidea</i> sp.	143
<i>Dactylospongia elegans</i>	144
<i>Ircinia echinata</i>	145
<i>Leucetta microraphis</i>	145
<i>Monanchora</i> sp.	146
<i>Oceanapia incrustata</i> (= <i>Rhizochalina incrustata</i>)	147
<i>Petrosia</i> sp.	147
<i>Stelletta</i> sp.	147
<i>Theonella swinhoei</i>	148
<i>Theonella</i> sp.	148
<i>Topsentia</i> sp.	149
<i>Xestospongia testudinaria</i>	150
<i>Xestospongia</i> sp. 1	151
<i>Xestospongia</i> sp. 2	151
<i>Xestospongia</i> sp. 3	151
ANTICANCER ACTIVITY OF POLYKETIDES OF MARINE SPONGES	152
<i>Axinella</i> sp.	152
<i>Cacospongia mycofijiensis</i>	152
<i>Candidaspongia</i> sp.	153
<i>Chondrosia corticata</i>	153
CHONDROPSIS SP.	154
<i>Discodermia dissoluta</i>	154
<i>Fascaplysinopsis</i> sp.	154
<i>Forcepia</i> sp.	154
<i>Halichondria (Halichondria) okadai</i>	155
<i>Hyatella</i> sp.	155
<i>Leiodermatium</i> sp.	155
<i>Lissodendoryx</i> sp.	156
<i>Lithoplocamia lithistoides</i>	156
<i>Negombata magnifica</i>	156
<i>Plakortis angulospiculatus</i>	157
<i>Plakortis halichondrioides</i>	157
<i>Spongia</i> sp.	157
<i>Theonella</i> sp.	158
Anticancer Activity of Miscellaneous Compounds of Marine Sponges	158
<i>Aphrocallistes beatrix</i>	158
<i>Axinella brevistyla</i>	159
<i>Callyspongia</i> sp.	159
<i>Coscinoderma mathewsi</i>	159
<i>Crambe crambe</i>	160
<i>Cymbastela cantharella</i>	160

<i>Dactylospongia metachromia</i> , (= <i>Hippospongia metachromia</i>)	160
<i>Discodermia calyx</i>	161
<i>Discodermia dissoluta</i>	161
<i>Haliclona</i> (<i>Soestella</i>) <i>mucosa</i>	162
<i>Hyrtios erectus</i>	162
<i>Ianthella</i> sp.	163
<i>Ircinia ramosa</i>	164
<i>Mycale hentscheli</i>	165
<i>Mycale</i> sp.	165
<i>Pachastrissa</i> sp.	166
<i>Petrosia</i> sp.	166
<i>Plakinastrella</i> sp.	166
<i>Plakortis angulospiculatus</i>	167
<i>Plakortis</i> sp.	167
<i>Pseudocerarina</i> sp. 1 (= <i>Psammaphysilla</i> sp.)	168
<i>Pseudoceratina</i> sp. 2 (= <i>Psammaphysilla</i> sp.)	168
<i>Tectitethya crypta</i> (= <i>Cryptotheca crypta</i>)	169
<i>Tedania</i> sp.	170
<i>Theonella</i> sp.	170
<i>Trachycladus spinispirulifera</i> (= <i>Spirastrella spinispirulifera</i>)	170
<i>Xestospongia</i> sp.	171
CONCLUSION	171
CHAPTER 6 ANTICANCER POTENTIAL OF MARINE CNIDARIANS	172
INTRODUCTION	172
Anticancer Compounds of Marine Hydrozoans (Phylum: Cnidaria; Class: Hydrozoa) and their Action Mechanisms	172
<i>Abylopsis eschscholtzii</i>	172
<i>Aeginura</i> Grimaldi, <i>Aegina citrea</i> , <i>Colobonema sericeum</i> and <i>Arctapodema</i> sp.	173
<i>Aequorea aequorea</i>	173
<i>Chlorohydra viridissima</i>	173
<i>Crossota rufobrunnea</i>	173
<i>Halecium muricatum</i> and <i>Halecium beanie</i>	173
<i>Halicreas minimum</i> and <i>Pantachogon Haeckel</i>	174
<i>Macrorhynchia philippina</i>	174
<i>Physalia physalis</i>	174
<i>Thuiaria breitfussi</i>	174
Anticancer Compounds of Marine Scyphozoans (Class: Scyphozoa) and their Action Mechanisms	175
<i>Atolla vanhoffeni</i>	175
<i>Aurelia aurita</i>	175
<i>Cassiopea xamachana</i>	175
<i>Chrysaora quinquecirrha</i>	175
<i>Cotylorhiza tuberculata</i>	175
<i>Cyanea capillata</i> and <i>Cyanea lamarckii</i>	176
<i>Cyanea capillata</i>	176
<i>Cyanea nozakii</i>	176
<i>Nemopilema nomurai</i>	176
<i>Pelagia noctiluca</i>	176
<i>Rhizostoma pulmo</i>	176

Anticancer Compounds of Marine Cubozoans (Class: Cubozoa) and their Action	
Mechanisms	177
<i>Chiropsalmus quadrigatus</i>	177
<i>Chironex fleckeri</i>	177
Anticancer Compounds of Marine Octocorals (soft corals) (Class: Anthozoa) and their	
Action Mechanisms	177
<i>Acalyigorgia inermis</i>	177
<i>Alcyonium paessleri</i>	178
<i>Alcyonium patagonicum</i>	179
<i>Alertigorgia</i> sp.	179
<i>Bellonella albiflora</i>	180
<i>Briareum asbestinum</i>	180
<i>Briareum excavatum</i>	181
<i>Briareum</i> sp.	182
<i>Carijoa riisei</i> (= <i>Telesto riisei</i>)	183
<i>Carijoa</i> sp. and <i>Lophogorgia</i> sp.	183
<i>Carijoa</i> sp.	184
<i>Clavularia viridis</i>	184
<i>Clavularia inflata</i>	184
<i>Clavularia koellikeri</i>	185
<i>Clavularia</i> sp.	185
<i>Dendronephthya gigantea</i>	185
<i>Dichotella gemmacea</i>	185
<i>Echinomuricea</i> sp. 1	187
<i>Echinomuricea</i> sp. 2	187
<i>Eunicea laciniata</i>	188
<i>Eunicea mammosa</i>	188
<i>Eunicea pinta</i>	189
<i>Eunicea succinea</i>	189
<i>Eunicella verrucosa</i>	190
<i>Gersemia fruticosa</i>	190
<i>Isis hippuris</i>	190
<i>Junceella juncea</i>	191
<i>Lemnalia philippinensis</i>	191
<i>Lemnalia tenuis</i>	191
<i>Leptogorgia punicea</i>	191
<i>Leptogorgia sarmentosa</i>	192
<i>Lobophytum crassum</i>	192
<i>Lobophytum hedleyi</i>	193
<i>Lobophytum michaelae</i>	193
<i>Muricella</i> sp.	193
<i>Nephtea</i> sp.	194
<i>Paraminabea acronocephala</i>	194
<i>Paramuricea</i> sp.	195
<i>Plexaurella grisea</i>	195
<i>Sarcophyton crassocaule</i>	195
<i>Sarcophyton trocheliophorum</i>	197
<i>Scleronephthya pallida</i>	197
<i>Simularia capillosa</i>	197
<i>Simularia flexibilis</i>	197
<i>Simularia gardineri</i>	198

<i>Silularia gibberosa</i>	199
<i>Sinularia inelegans</i>	199
<i>Sinularia leptoclados</i>	199
<i>Sinularia</i> sp.	200
<i>Solenopodium excavatum</i>	200
<i>Subergorgia suberosa</i>	200
<i>Virgularia juncea</i>	202
<i>Xenia blumi</i>	203
<i>Xenia elongata</i>	203
<i>Xenia faraunensis</i>	204
<i>Xenia florida</i>	204
<i>Xenia novae-britanniae</i>	204
<i>Xenia umbellata</i>	205
<i>Xenia</i> sp.	208
ANTICANCER COMPOUNDS OF MARINE STONY AND BLACK CORALS (CLASS: ANTHOZOA) AND THEIR ACTION MECHANISMS	208
Epizoanthus sp.	208
<i>Montipora digitata</i>	208
<i>Montipora</i> sp. 1	208
<i>Montipora</i> sp. 2	208
<i>Palythoa toxica</i>	209
<i>Palythoa liscia</i>	209
<i>Tubastrea faulkneri</i>	209
Anticancer Compounds of Sea Anemones (Class: Anthozoa) and their Action Mechanisms	210
<i>Actinia equina</i>	210
<i>Aiptasia mutabilis</i>	210
<i>Anemonia sulcata</i>	210
<i>Bunodosoma caissarum</i>	210
<i>Bunodeopsis globulifera</i>	210
<i>Radianthus crista</i> (= <i>Heteractis crista</i> ; <i>Radianthus macrodactylus</i>)	210
<i>Sagartia rosea</i>	211
<i>Urticina piscivora</i>	211
CONCLUSION	216
CHAPTER 7 ANTICANCER POTENTIAL OF MARINE BRYOZOANS	217
INTRODUCTION	217
Anticancer and Cytotoxic Metabolites of Marine Bryozoans	218
Anticancer Alkaloid Compounds of Marine Bryozoans	218
<i>Amathia convoluta</i>	218
<i>Amathia tortuosa</i>	219
<i>Amathia wilsoni</i>	220
<i>Aspidostoma giganteum</i>	220
<i>Biflustra perfragilis</i>	221
<i>Caulibugula intermis</i>	221
<i>Chartella papyracea</i>	221
<i>Cryptosula pallasiana</i>	222
<i>Flustra foliacea</i>	222
<i>Paracribricellina cribraria</i>	223
<i>Pterocella vesiculosa</i>	223
<i>Securiflustra securifrons</i>	224
<i>Tegella spitzbergensis</i>	224

<i>Terminoflustra (Chartella) membranaceotruncata</i>	226
<i>Virididentula (Bugula) dentata</i>	226
Anticancer Lactone Compounds of Marine Bryozoans	227
<i>Bugula neritina</i>	227
<i>Myriapora truncata</i>	228
<i>Cryptosula pallasiana</i>	229
CONCLUSION	230
CHAPTER 8 ANTICANCER POTENTIAL OF MARINE SHELLFISH	231
INTRODUCTION	231
MARINE CRUSTACEANS	232
Shrimps	232
<i>Litopenaeus vannamei</i>	232
<i>Penaeus indicus</i>	232
Lobster and Shrimp Shell Wastes	232
Marine Crabs	233
<i>Calappa calappa</i>	233
<i>Chionoecetes opilio</i>	233
<i>Portunus segnis</i>	233
<i>Serratia marcescens</i>	233
Chitosan Derived from Crab Shell Wastes	233
MARINE MOLLUSCS	234
Marine Bivalves	234
<i>Atactodea striata</i>	234
<i>Bathymodiolus thermophilus</i>	234
<i>Crassula aequilatera</i>	235
<i>Crassostrea gigas</i>	235
<i>Meretrix lusoria</i>	235
<i>Mytilus edulis</i>	235
<i>Paphia malabarica</i>	235
<i>Paphies donacina</i>	236
<i>Spisula murchisoni</i> (= <i>Mactra murchisoni</i>)	236
<i>Spisula polynyma</i> (= <i>Mactromeris polynima</i>)	236
<i>Tegillarca granosa</i>	236
<i>Villorita cyprinoides</i>	237
MARINE GASTROPODS	237
Terpenes and Steroids	237
<i>Aplysia angasi</i> (= <i>Aplysia dactylomela</i>)	237
<i>Aplysia depilans</i>	239
<i>Aplysia fasciata</i>	239
<i>Aplysia kurodai</i>	239
<i>Aplysia oculifera</i>	240
<i>Aplysia punctata</i>	240
<i>Austrodoris kerguelenensis</i>	241
<i>Chelynotus semperi</i>	241
<i>Chromodoris obsoleta</i> (= <i>Goniobranchus obsoletus</i>)	241
<i>Chromodoris inornata</i> (= <i>Chromodoris aspersa</i>)	242
<i>Dicathais orbita</i>	243
<i>Dolabella auricularia</i>	243
<i>Elysia subornata</i>	244
<i>Jorunna funebris</i>	244

<i>Leminda millecra</i>	245
<i>Phidiana militaris</i>	245
<i>Phyllidia coelestis</i>	245
<i>Pleurobranchus albiguttatus and Pleurobranchus forskalii</i>	246
<i>Reticulidia fungia</i>	246
<i>Trimusculus costatus</i>	247
<i>Trimusculus peruvianus</i>	247
Peptides and Depsipeptides	247
<i>Dolabella auricularia</i>	247
<i>Onchidium</i> sp.	248
<i>Pleurobranchus forskalii</i>	249
<i>Philinopsis speciosa</i>	249
Polyketides	250
<i>Aplysia kurodai</i>	250
<i>Chromodoris lochi</i>	251
<i>Chromodoris lochi, Chromodoris elisabethina, Chromodoris kuiteri, Chromodoris annae, and Chromodoris magnifica</i>	252
<i>Dolabella auricularia</i>	252
<i>Glossodoris quadricolor (= Chromodoris quadricolor)</i>	253
<i>Hexabranhus sanguineus</i>	253
<i>Kelletia kelleitii</i>	255
<i>Onchidium</i> sp.	255
<i>Peltodoris atromaculata</i>	255
Nitrogen Containing Compounds	256
<i>Aplysia kurodai</i>	256
<i>Bursatella leachii and Stylocheilus longicauda</i>	257
<i>Coriocella nigra</i>	258
Staurosporine analogues	258
<i>Dolabella auricularia</i>	258
<i>Lamellaria</i> sp.	258
<i>Roboastra tigris</i>	259
<i>Tambja ceutae</i>	259
<i>Turbo coronatus</i>	260
<i>Turbo stenogyrus</i>	260
<i>Tylodina perversa</i>	260
Cephalopods	261
<i>Sepiella inermis (= Sepiella maindroni)</i>	262
<i>Uroteuthis (Photololigo) duvaucelii (=Loligo duvaucelii)</i>	262
<i>Octopus vulgaris</i>	262
ECHINODERMS	262
Starfish	262
<i>Acanthaster planci</i>	262
<i>Anthenea aspera</i>	263
<i>Anthenea chinensis</i>	264
<i>Anthenea sibogae</i>	264
<i>Archaster typicus</i>	265
<i>Asterias amurensis</i>	266
<i>Asterina pectinifera</i>	266
<i>Asteropsis carinifera</i>	267
<i>Astropecten polyacanthus</i>	267
<i>Astropecten monacanthus</i>	269

<i>Certonardoa semiregularis</i>	269
<i>Choriaster granulatus</i>	269
<i>Craspidaster hesperus</i>	270
<i>Ctenodiscus crispatus</i>	271
<i>Culcita novaeguinea</i>	271
<i>Echinaster luzonicus</i>	273
<i>Henricia leviuscula</i>	273
<i>Hippasteria phrygiana</i>	274
<i>Leptasterias ochotensis</i>	274
<i>Lethasterias fusca</i>	275
<i>Narcissia canariensis</i>	275
<i>Pentaceraster gracilis</i>	275
Brittle Stars	277
<i>Ophiocoma erinaceus</i>	277
<i>Ophioderma longicauda</i>	277
<i>Ophiocoma scolopendrina</i>	278
<i>Ophiomastix mixta</i>	279
<i>Ophioplocus japonicus</i>	279
<i>Ophiura sarsii</i> , <i>Ophiura ooplax</i> and <i>Gorgonocephalus cf. eucnemis</i>	280
Sea Urchins	281
<i>Diadema savignyi</i>	281
<i>Mesocentrotus nudus</i> and <i>Scaphechinus mirabilis</i>	282
<i>Paracentrus lividus</i>	282
<i>Strongylocentrotus intermedius</i>	283
<i>Strongylocentrotus nudus</i>	283
<i>Strongylocentrotus purpuratus</i>	283
<i>Toxopneustes pileolus</i> and <i>Tripneustes gratilla</i>	283
Crinoids	283
<i>Comantheria rotula</i>	283
<i>Comanthus</i> sp.	285
<i>Comatula rotalaria</i>	286
Sea Cucumbers	286
<i>Apostichopus (Stichopus) japonicus</i> (= <i>Stichopus japonicus</i>)	286
<i>Cucumaria frondosa</i>	286
<i>Cucumaria japonica</i>	287
<i>Cucumaria okhotensis</i>	288
<i>Holothuria atra</i>	289
<i>Holothuria leucospilota</i>	290
<i>Holothuria leucospilota</i> , <i>Holothuria parva</i> and <i>Holothuria scabra</i>	290
<i>Holothuria nobilis</i>	290
<i>Mensamaria intercedens</i>	291
<i>Pearsonothuria graeffei</i>	292
<i>Pentacta quadrangulari</i>	293
<i>Psolus fabricii</i> and <i>Stichopus chloronotus</i>	294
<i>Stichopus chloronotus</i>	294
<i>Stichopus japonicus</i>	294
<i>Stichopus variegatus</i>	294
CONCLUSION	296
CHAPTER 9 ANTICANCER POTENTIAL OF MARINE CHORDATES	297
INTRODUCTION	297

Tunicates	297
<i>Aplidium altarium</i>	298
<i>Aplidium caelestis</i>	298
<i>Aplidium conicum</i>	299
<i>Aplidium cyaneum</i>	300
<i>Aplidium densum</i>	301
<i>Aplidium elegans and Ciona edwardsii</i>	301
<i>Aplidium glabrum</i>	301
<i>Aplidium glabrum</i>	302
<i>Aplidium longithorax</i>	303
<i>Aplidiopsis confluata</i>	304
<i>Ascidia mentula</i>	304
<i>Botryllus tuberatus</i>	304
<i>Botryllus tyreus</i>	305
<i>Ciona edwardsii</i>	306
<i>Clavelina phlegraea</i>	306
<i>Cnemidocarpa bicornuta</i>	306
<i>Cystodytes dellechiaiei</i>	307
<i>Cystodytes violatinctus</i>	307
<i>Cystodytes</i> sp.	308
<i>Didemnum granulatum</i>	308
<i>Didemnum lahillei, Aplidium glabrum, and Molgula manhattensis</i>	308
<i>Didemnum molle</i>	308
<i>Didemnum moseleyi</i>	309
<i>Didemnum obscurum</i>	310
<i>Didemnum proliferum</i>	311
<i>Didemnum psammatodes</i>	312
<i>Didemnum. rubeum</i>	312
<i>Didemnum</i> sp.	313
<i>Didemnum</i> sp. 1	313
<i>Didemnum</i> sp. 2	314
<i>Didemnum</i> sp. 3	314
<i>Diplosoma virens</i>	314
<i>Diplosoma</i> sp.	315
<i>Distaplia regina</i>	315
<i>Eudistoma gilboviride</i>	316
<i>Eudistoma toealensis</i>	316
<i>Eudistoma vannamei</i>	317
<i>Eudistoma</i> sp.	317
<i>Halocynthia papillosa and Halocynthia roretzi</i>	318
<i>Leptoclinides dubius</i>	319
<i>Lissoclinium badium</i>	320
<i>Lissoclinium notti</i>	322
<i>Lissoclinium</i> sp. 1	323
<i>Lissoclinium</i> sp. 2	324
<i>Microcosmus vulgaris</i>	325
<i>Perophora namei</i>	325
<i>Phallusia fumigata</i>	325
<i>Phallusia nigra</i>	326
<i>Policitor adriaticus</i>	326
<i>Polyandrocaroa zorritensis</i>	326

<i>Polycarpa aurata</i>	327
<i>Pseudodistoma megalarva</i>	328
<i>Sidnyum turbinatum</i>	329
<i>Stolonica</i> sp.	329
<i>Syncarpa oviformis</i>	330
<i>Synoicum adareanum</i>	331
<i>Synoicum pulmonaria</i>	331
<i>Synoicum</i> sp.	332
<i>Trididemnum cyclops</i>	332
Unidentified tunicate sp. 1	333
Unidentified tunicate sp. 2	333
Unidentified tunicate sp. 3	333
Unidentified tunicate sp. 4	334
MARINE FISHES	337
Elasmobranchs	337
<i>Centroscymnus coelepis</i>	337
<i>Prianace glauca</i>	337
<i>Squalus acanthias</i>	338
<i>Okamejei kenojei</i>	338
Teleosts	338
<i>Epinephelus coioides</i>	338
<i>Epinephelus lanceolatus</i>	338
<i>Exocoetus volitans</i>	339
<i>Gadus morhua</i> , <i>Lethrinus atlanticus</i> , <i>Micromesistius poutassou</i> , <i>Puronectes platessa</i> , and <i>Salmo salar</i>	339
<i>Lates calcarifer</i>	339
<i>Nemipterus japonicus</i>	339
<i>Onchorhynchus keta</i>	339
<i>Pardachirus marmoratus</i>	339
<i>Platycephalus fuscus</i>	339
<i>Plicofollis dussumieri</i> (= <i>Tachysaurus dussumieri</i>)	339
<i>Setipinna taty</i>	340
<i>Syngnathus acus</i>	340
<i>Thunnus tonggol</i>	340
CONCLUSION	340
REFERENCES	341
SUBJECT INDEX	579

FOREWORD

I am very much pleased to write my Foreword for this inter-disciplinary title "Medicinal Chemistry and Marine Life: Anticancer Drugs Sourced from Marine Life" relating to an untouched aspect of Fisheries and Pharmaceutical disciplines.

Cancer is an increasing public health hazard and about 60% of the anticancer drugs of natural origin are presently in use to treat this disease. Owing to the tumor cells resistance to drugs, and undesirable side effects observed with the synthetic drugs, there is an urgent need for the development of new anticancer drugs. In this regard, the marine environment, an exceptional reservoir of anticancer compounds, has paved way for further investigations on the utilization of its vast biodiversity. Comparing with terrestrial organisms, marine organisms do not have a distinguished history of use in traditional medicine. But during the last 50 years, advances in new technologies and engineering opened up the marine environment to large scale scientific exploration. Despite considerable challenges, 11 marine biota-derived anticancer drugs arrived in the market and are currently used in therapeutics.

The present title, first of its kind deals with the major constituents of marine life with promising anticancer compounds and in my opinion, this publication could serve as a potential resource for teachers and students of both Marine and Pharmaceutical Sciences besides serving as a reference for anticancer agents from marine source.

I congratulate the authors for their timely contribution.

K.N. Selvakumar
Tamil Nadu Veterinary and Animal Sciences University
Chennai, India

PREFACE

Cancer remains one of the most life-threatening diseases and its prevalence is increasing worldwide especially in countries that are witnessing urbanization and rapid industrialization changes. In 2018 alone, about 18 million new cases of cancer were reported globally, resulting in approximately 10 million deaths. Cancer treatments do not have potent medicine as the currently available drugs are causing side effects in some instances. Hence, identifying novel effective drugs is urgently needed, and many ongoing research programs are in the process of identifying new anti-cancer drugs from marine organisms which are considered “blue drug banks” of unique anti-cancer compounds with diverse groups of chemical structures. Seven marine-based pharmaceuticals have so far been approved for marketing; 23 compounds are in clinical trials between phases I and III; and over one thousand compounds isolated from marine organisms are undergoing preclinical studies. It is worthy of mention here that among those marine organism-derived compounds in clinical use, four compounds viz. cytarabine (Cytosar®), trabectedin (Yondelis®), eribulin mesylate (Halaven®) and the conjugated antibody brentuximab vedotin (Acentris®) are used in the treatment of cancer.

Though a few books are presently available on marine natural products and pharmaceutical marine life, a comprehensive volume dealing with the biodiversity of marine organisms yielding anticancer compounds has not so far been published. This interdisciplinary publication first of its kind would answer this long-felt need. It deals mainly with the ecology, and biology of marine organisms yielding anticancer compounds and their mechanism of action. It is hoped that the present publication when brought out would be of great use as a standard text-cum-reference for teachers, students, and researchers of various disciplines such as biomedical sciences, pharmaceutical sciences, marine biology, and fisheries science; a valuable reference for libraries of colleges and universities; and as a guide for the pharmaceutical industries involved in the development of new marine-derived anticancer drugs.

Ramasamy Santhanam

Fisheries College and Research Institute
Tamil Nadu Veterinary and Animal Sciences University, Thoothukudi-628008
India

Santhanam Ramesh

Karuna College of Pharmacy, Kerala University of Health Sciences
Thirumittacode, Palakkad 679 533, Kerala
India

Subbiah Balasundari

Dr.M.G.R. Fisheries College and Research Institute, Tamil Nadu Fisheries University
Thalainayeru, Tamil Nadu 614712
India

&

Sheba R. David

School of Pharmacy, University of Wyoming, Laramie, Wyoming 82071-3375
USA

CHAPTER 1**Introduction**

Abstract: This chapter deals with the approved drugs sourced from marine biota, the pathophysiology of cancer, the anticancer potential of marine organisms, the most promising marine biota-derived anticancer compounds for the different types of human and cancer, biogeography of marine invertebrate species yielding anti cancer compounds, major constraints in the development of anticancer drugs and the remedial measures.

Keywords: Approved marine drugs, Anticancer marine compounds, Cancer pathophysiology, Constraints in marine anticancer drug development, Human cancer types, Marine biota, Remedial measures.

INTRODUCTION

The total global biodiversity in terms of both prokaryotic and eukaryotic organisms has been estimated as 500×10^6 species and in the marine ecosystems, about 250,000 species have been described. These marine organisms produce secondary metabolites as their defense tools to resist predators and facilitate their survival in extreme environmental conditions such as variations in temperatures, salinity, pressure, *etc.* Such secondary metabolites of marine organisms have been reported to offer extraordinary chemical and pharmacological scope. While marine flora such as seaweeds and mangroves have been used for medicinal purposes worldwide since ancient times, marine invertebrate animals have attracted the attention of researchers only in the last 50 years. It is worthy of mention here that less than 5% of the deep sea has only been explored till now and less than 0.01% of the deep-sea floor has been sampled thoroughly [1].

Approved Drugs Sourced from Marine Biota

The marine environment has been reported to possess immeasurable chemical diversity and it is an extraordinary resource for therapeutically important chemicals. The unique structural scaffolds and biological modes of action of these

chemicals make them lead compounds in drug discovery. Research on the secondary metabolites of marine organisms began only in the 1950s with Bergmann and coworkers' discovery of spongothymidine and spongouridine derived from the Caribbean sponge *Tectitethya crypta*. The reports on the geographic origin of the marine compounds showed that Australia contributed almost a quarter (24%) of these compounds followed by the South China Sea (18%) and the Pacific Ocean (17%) [2]. To date, more than 28,000 compounds derived from marine organisms have been reported and more than 1000 new marine-derived compounds have been discovered each year since 2008. Although the number of promising bioactive compounds from the marine biota is on the increase, the search for marine biota-derived drugs is relatively recent, and only in the middle part of the 20th century, the scientists began to systematically probe the seas and oceans for new drugs. Today, the pipeline process from the basic research of a bioactive molecule to the regulatory approval by the Food and Drug Administration (FDA) takes about 15 years and costs several million dollars. However, it is also worth of mentioning here that less than 12% of the potential drugs get final approval [3]. The stages and time estimates in the development and approval of a drug are given in Table 1.

Table 1. Stages and Time Estimates in the Development and Approval of Drugs [3].

Stage	Estimated Time (Yrs)
Basic Research and Drug discovery	5
Preclinical Trials	1.5
Clinical Trials (Phase I,II & III)*	6
FDA Review	2
Large Scale Manufacturing	2

* Number of Volunteers: Phase I, Tens; Phase II, Hundreds; Phase III, Thousands.

Cancer as a Major Public Health Problem

Cancer has been reported to be a major public health problem worldwide and is the second leading cause of death in the United States. As per the report of the US National Cancer Institute, 21 million new cases may appear in the coming two decades. Africa, Asia, and Central and South America are considered to be the most vulnerable countries where 7 out of 10 deaths are due to malignant neoplasms termed as cancer. However, tumor and cancer are also interchangeably used occasionally. The deadliest cancers are believed to be lung cancer, breast cancer, prostate cancer, colon cancer, pancreatic cancer, liver cancer, ovarian cancer, leukemia, non-Hodgkin's lymphoma, and corpus and uterus cancer. Among the usual cancer treatment forms *viz.* surgery, radiotherapy, and

chemotherapy, the former two are primarily indicated for solid tumors and chemotherapy assumes greater significance as this systemic drug-based treatment is known to interfere with the process of growth and cell division in tumor cells. Further, this chemotherapy is currently undergoing a significant revolution due to the introduction of a very large number of new arsenal drugs and less side effects of such target-oriented drugs. However, these drugs have not yielded the desired results; and recurrence of tumor and onset of metastasis often occur with such therapies. Therefore, there is an urgent need to search for new compounds with greater therapeutic potency and fewer side effects. In this connection, the seas and oceans could play an important role with their huge pharmaceutical biodiversity in general and anticancer potential in particular.

Pathophysiology of Cancer

In the development of cancer in the human body, several stages are involved. A normal cell may get damaged by either endogenous genetic and biological factors or exogenous factors like human diet and body mutation. Such damaged cells may either attain apoptosis (cell death) or undergo uncontrolled cell division which leads to mass forming and finally neoplasia. The neoplasia is nothing but the uncontrolled, abnormal growth of cells which is termed a neoplasm or tumor. The tumor may be benign (gentle) or become malignant (cancer). Generally, a balance between proliferation and programmed cell death is maintained in the form of apoptosis under normal conditions by regulating both processes tightly. On the other hand, in carcinogenesis, normal cells are transformed into cancer cells.

Anticancer Potential of Marine Organisms

Owing to their diverse and highly complex habitats and lifestyle, the marine species represent a largely unexplored source of potential anticancer agents. The anticancer compounds are mainly derived from mollusk/cyanobacterium (blue-green algae) (64%), sponge (14%), tunicate(14%), bacterium (4%) and fungus (4%) in that order. It is also worthy of mention here that 7 marine biota-based drugs have so far been approved for marketing; 23 compounds are in clinical trials between phases I and III; and more than one thousand compounds are undergoing preclinical studies. Further, among those marine biota-derived drugs in clinical use, 4 drugs *viz.* cytarabine (Cytosar®), trabectedin (Yondelis®), eribulin mesylate (Halaven®) and the conjugated antibody brentuximab vedotin (Acentris®). are presently used in the treatment of cancer [4]. A total of about 560 anticancer compounds have so far been derived from marine organisms (invertebrates) and both sponges and cnidarians contribute to more than 85% as shown in Table 2.

Marine Bio-Chemical Diversity: Promising Anticancer Groups

Abstract: This chapter deals with marine biodiversity and its constituents possessing anticancer activity. The different potential groups of marine plants such as microalgae (*e.g.* cyanobacteria), macroalgae (seaweeds), seagrasses, and mangroves; marine invertebrates *viz.* sponges, cnidarians, bryozoans, molluscs, and echinoderms; and tunicates among chordates producing anticancer compounds have been identified. The chemical diversity of anticancer compounds representing different chemical classes *viz.* alkaloids, terpenes, peptides, polyketides, polyphenols, glycosides *etc.* is also dealt with.

Keywords: Anticancer marine biodiversity, Anticancer chemical diversity, Anticancer marine plants, Anticancer marine invertebrates.

INTRODUCTION

According to the World Register of Marine Species (WoRMS), the known marine species are about 240,000. Many of these species are influenced by environmental factors, such as temperature, pressure, pH, light, salinity, *etc.* which make them produce secondary metabolites for helping the species in their communication, defense/offense, or competition. Depending on their molecular targets and structural features, these compounds are known to share different anticancer activities. The therapeutic importance of marine biodiversity was made known only after the chemical investigation of the first marine organism *viz.* the Caribbean sponge (*Cryptotethya crypta*) [1]. Subsequently, the anticancer importance of marine organisms such as marine plants (microalgae such as diatoms, dinoflagellates, and cyanobacteria; macroalgae (seaweeds), seagrasses, and mangroves; and marine invertebrates (sponges, cnidarians, bryozoans, molluscs, and echinoderms); and tunicates has been reported.

Promising Anticancer Marine Biodiversity

Marine Microalgae

Among the marine microalgae, certain species of green algae, blue-green algae (cyanobacteria), golden-brown, and yellow algae, yellow-green algae (diatoms), dinoflagellates, and red alga have been reported to possess anticancer compounds. Among these components, the cyanobacteria (blue-green algae) however, dominate with their larger number of anticancer species.

The peptide and polyketide metabolites of this microalgae have been reported to be effective for inducing apoptotic death of cancer cells or by affecting cell signaling *via* activation of the protein kinase c family. About 50% of the 41 screened strains of cyanobacteria have shown the ability to cause cancer cell death [1]. The anti-microtubule agents, *i.e.*, dolastatin 10 and curacin A of these cyanobacterial strains have been clinically evaluated for the treatment of cancer and these compounds are believed to serve as lead drug candidates for the synthesis of a number of analogs/derivatives. Recent research findings have shown that the under-exploited benthic cyanobacteria from temperate marine areas could be novel drug sources against leukemia. Further intensive investigations are therefore urgently needed on the potential anticancer activities and clinical uses of these marine cyanobacterial species.

Macroalgae (Seaweeds)

Marine macroalgae or seaweeds form an important component of marine ecosystems due to their large habitats, high biodiversity, and specific living conditions. They have long been considered as food and functional food due to their important bioactive elements including carotenoids, dietary fiber, protein, essential fatty acids, vitamins (A, B, B12, C, D, E), and minerals such as Ca, P, Na, and K [1]. These algae have also served as potential drug sources as they possess a vast number of major secondary metabolites such as terpenes, polyphenols, polysaccharides, phlorotannins, phycobiliproteins, carotenoids, and pigments. Among these chemical classes, the compounds of terpenes, polysaccharides, and polyphenols are of great interest for their antitumor activity. The anticancer compounds from these seaweeds have been reported to induce cancer cell death *via* various signaling pathways and mechanisms. Further, these compounds prevent resistance or tolerance of cancer cells. For example, the sulfated polysaccharide, fucoidan of the different species of seaweeds acts as an anticancer agent through various signaling pathways which include cell cycle arrest, apoptosis, and anti-angiogenesis by inhibiting vascular endothelial growth factor formation, and natural killer cell activation.

Mangrove Plants

Mangroves are halophytic (salt-tolerant) plants and they grow on brackish water coasts and intertidal seawater systems of the tropical and subtropical coastlines. The world mangroves occupy the major geographic regions viz. east area mangroves from the west and central Pacific to the southern end of Africa; west area covering the west coast of Africa and both east and west coasts of the Americas. These mangroves are considered to be one of the most ecologically and economically significant ecosystems due to their wide range of services which include, carbon storage and sequestration, enhancement of fisheries, and coastal protection against natural disasters. Further, these ecosystems, protect the nearby marine ecosystems and improve their quality through nutrient cycling and by neutralizing the pollutants originating from aquatic and terrestrial means. Furthermore, they support commercially important marine life and wildlife by providing them with habitat and food. Several species of mangroves are of great application value in various industrial sectors such as pharmaceuticals, cosmetics, and materials. In recent decades, these plants have also attracted the attention of researchers due to their unique secondary metabolites with various bioactivities in general and anticancer activity in particular. For example, triterpenoid compounds xylogranatins A-D; and limonoids granaxylocapins A, B derived from the mangrove *Xylocarpus granatum* have been reported to possess cytotoxicity in various cancer cell lines including P-388 leukemia [8].

Marine Invertebrates

Marine Sponges

Marine sponges belong to the phylum Porifera with four classes: viz. Calcarea, Demospongiae, Hexactinellida, and Homoscleromorpha. The known and described species of this phylum are more than 9000. These sessile invertebrates represent the richest source of marine bioactive compounds. Of the 28,000 new compounds of marine origin identified so far, the sponges and their associated microorganisms contribute to about 30% with 5300 compounds. The chemical classes of these secondary metabolites include alkaloids, terpenes, amino acid derivatives, cyclic peptides, nucleosides, sterols, peroxides, fatty acids, etc. Among these compounds, about 60 of them have been reported to possess chemopreventive and/or anticancer potential [9]. The successful discovery and identification of spongothymidine and spongouridine from the Caribbean sponge *Tethya crypta* led to the development of a clinically anticancer agent viz. AraC (cytosine arabinoside); and Eribulin, a synthetic version of halichondrin B, produced by the sponge *Halichondria okadai* has shown potential activity against pretreated metastatic breast cancer cells [1]. The origin of the secondary

Marine Biota-based Anticancer Drug Candidates in Pipeline

Abstract: This chapter deals with the approved and marketed anticancer drugs derived from marine sponges, mollusks/cyanobacteria, and tunicates; marine biota-derived anticancer compounds in clinical trials *i.e* in III, II, and I phases; and bioactive new chemical entities (NCEs) with anticancer function from marine biota. Limiting factors in the development and approval of drugs from marine biota and significant challenges in the development and approval of marine drugs are also given.

Keywords: Challenges in drug development, Clinical trials, Marine anticancer drugs, New chemical entities, Limiting factors.

INTRODUCTION

In recent decades, the hallmarks of cancer have been updated every now and then owing to its complexity. From 2010 onwards, several marine biota-derived drugs have been approved by the Food and Drug Administration (FDA) (USA) and other world regulatory authorities for the treatment of various types of cancer. Such marketed drugs include panobinostat and eribulin mesylate from marine sponges; plitidepsin, lurbnectedin and trabectedin from the tunicates; and brentuximab vedotin; polatuzumab vedotin; enfortumab vedotin; belantamab mafodotin; disitamab vedotin; and tisotumab vedotin from the marine mollusk-associated cyanobacteria. Based on their structural features and molecular targets, these compounds possess various modes of action in anticancer activities.

APPROVED AND MARKETED ANTICANCER DRUGS DERIVED FROM MARINE SPONGES

The marine bio-drug discovery started in the 1960s, and some bioactive compounds were approved. Among them, the oldest antileukemic compound *viz*, Cytarabine ARA-C was isolated in 1959 from the marine sponge *Tethya crypta* by Walwick at the University of California. Subsequently, two anticancer synthetic

analogues—derivatives, developed from lead molecules of these sponges were approved [18] and they are discussed below:

Eribulin Mesylate (E7389, Halaven®)

The eribulin mesylate is the simplified synthetic analog of halichondrin B, which is a macrolide molecule derived from the marine sponge *Halichondria okadai* (Phylum: Porifera; Class: Demospongiae). Halichondrin B was found to show cytotoxic activity in murine models of solid tumors and leukemia. Due to the low yields of this compound from the above sponge species, the production of synthetic halichondrin B was necessitated, and subsequently, many analogs, like eribulin mesylate were developed. Eribulin is presently used for treating metastatic breast cancer. In 2010, it was approved in the USA by the FDA as Halaven® and by the European Medical Agency (EMA) in 2011 [18].

Panobinostat (LBH-589, Farydak®)

Panobinostat is a synthetic analog of Psammaplyn A, which was derived from the marine sponge, *Pseudoceratina purpurea* (Class: Demospongiae). After the discovery of this compound, many derivatives like psammaplyn B-D and biprasin and psammaplyn E-J were obtained [18].

The observed features of the approved compounds derived from the marine sponges are given in Table 1.

Table 1. Approved compounds derived from the marine sponges [18].

Compound	Chemical Class	Source Species	Mode of Action
Eribulin mesylate	Macrolide	<i>Halichondria okadai</i>	Interfering tubulin polymerization
Panobinostat	Hydroxamic acid derivative	<i>Pseudoceratina purpurea</i>	Histone deacetylase (HDAC) inhibitor; Aminopeptidase-N and DNA Methyltransferase inhibitor

APPROVED AND MARKETED ANTICANCER DRUGS DERIVED FROM MARINE MOLLUSKS/CYANOBACTERIA ASSOCIATION

In recent years, several antibody-drug conjugates (ADCs) have been approved. Such ADCs were derived from the anticancer molecules produced by the symbiosis of cyanobacteria (blue-green algae) and molluscs. For the development of these anticancer drugs, the cyanobacterial species, *Symploca hynoides* and *Lyngbya majuscula*; and molluscan species *Dolabella auricularia* were the significant contributors [18]. The description of the approved and marketed

anticancer drugs derived from marine mollusks/cyanobacteria association [18] is given below.

Brentuximab Vedotin ((SGN-35, Adcetris®)

For this approved ADC, the linear pentapeptides dolastatins produced by the sea hare, *Dolabella auricularia* (Phylum: Mollusca; Class: Gastropoda) were the contributing compounds. However, the production of these compounds was subsequently found to be due to *Symploca hydroides* and *Lyngbya majuscula* (Phylum: Cyanobacteria; Order: Oscillatoriales), the diet species of the mollusc.

Polatuzumab Vedotin

This is another approved ADC.

Enfortumab Vedotin-Eifv (Padcev®)

This FDA-approved drug treats metastatic or locally advanced urothelial cancer.

Disitamab Vedotin

This approved ADC has been reported to regulate cell duplication, proliferation and apoptosis. The antibody present in this molecule is believed to be used as a target for anticancer compounds.

Tisotumab Vedotin-tftv (Tivdak®)

It is a vedotin ADC associated with a specific antibody. It is for the treatment of cervical, ovarian and bladder cancers.

Belantamab Mafodotin-blmf (Blenrep®)

It is a recently approved drug by the FDA and European Medicines Agency (EMA) and is used for treating relapsed or refractory multiple myeloma.

The chemical class and mode of action of the approved anticancer drugs derived from the marine mollusks/cyanobacteria association are given in Table 2.

Table 2. Approved anticancer drugs derived from the marine mollusks/cyanobacteria association [18].

Compound	Chemical Class	Source Species Mollusc/Cyanobacteria	Mode of Action
Brentuximab vedotin (Fig. 11)	ADC (MMAE + CD30)	<i>Dolabella auricularia</i> / <i>Symploca hydroides</i> , <i>Lyngbya majuscula</i>	Microtubulin targeting agent via CD 30

Anticancer Potential of Marine Plants

Abstract: This chapter identifies the potential species of the various groups of marine plants such as microalgae (microscopic green algae, blue-green algae, golden-brown, and yellow algae, yellow-green algae and dinoflagellates and red alga), macroalgae or seaweeds *viz.* green algae, brown algae and red algae), seagrasses, mangrove plants, and halophytes; and their anticancer compounds with the mechanism of actions.

Keywords: Anticancer compounds, Halophytes, Microalgae, Macroalgae, Mangrove plants, Mechanism of action, Seaweeds, Seagrasses.

INTRODUCTION

Marine medicinal plants include microalgae, macroalgae (seaweeds), seagrasses, mangroves and halophytes. Among these, marine microalgae, seaweeds (macroalgae) and mangroves have been reported to possess significant pharmaceutical compounds of human health value. The microalgae such as cyanobacteria (blue-green algae), golden-brown and yellow algae, yellow-green algae (diatoms) and dinoflagellates are considered to be excellent sources of pigments, lipids, carotenoids, omega-3 fatty acids, polysaccharides, vitamins, *etc.*, and there is an increasing demand for their use as nutraceuticals and food supplements. Some microalgae such as cyanobacteria and dinoflagellates are known for their anti-cancer activity. The seaweeds (macroalgae) also have been reported to have several health-promoting natural products such as sulphated polysaccharides, polyphenolics, terpenoids, flavonoids, pigments, MUFAs (monounsaturated fatty acids), PUFAs (polyunsaturated fatty acids), and HUFAs (highly unsaturated fatty acids), essential amino acids, vitamins, and essential minerals. These compounds are believed to be of great use in the development of new pharmaceutical and nutraceutical products. While the bioactive compounds of these algae have several bioactivities including anti-tumor effects, their nutraceutical products are known to prevent human health problems like diabetes, cancer and cardiovascular diseases. Similarly, mangrove plants like *Rhizophora stylosa*, *Sonneratia paracaseolaris*, *Aegiceras corniculatum*, *Excoecaria agallocha*, *Bruguiera cylindrica*, *Ceriops taga*, and *Xylocarpus* spp. have been

reported to possess potent anti-tumor compounds. In this chapter, the most promising species of marine plants, their anticancer compounds, and their modes of action are dealt with.

Microalgae

Green Algae

Chlorella ellipsoidea

The carotenoid extract of this species acted against HCT-116 (colon carcinoma) cell line and an IC₅₀ value of 40 µg/mL was recorded [3].

Chlorella sorokiniana

At an active concentration of 0.0156 to 1 µg/mL, its water extract displayed inhibitory activity against lung adenocarcinoma (CL1-5), and the cell viability was reduced to 20% progressively [3].

Chlorella sp.

The extracts of the species of *Chlorella* viz. *Chlorella spaerckii*, *Chlorella stigmatophora*, *Chlorella salina*, *Chlorella marina*, and *Chlorella ovalis*, which possess peptides have shown antiproliferative activity and cytotoxicity induced by ultraviolet B (UVB). Further, these compounds decreased cleaved PARP-1; prevented DNA damage and fragmentation; and reduced pFADD expression [23].

Dunaliella tertiolecta

A glycolipid compound, glycerol 1-(9Z, 12Z, 15Z-octadecatrienoate)-2-(4Z,7Z,10Z, 13Z-hexadecatetraenoate)-3-O-β-D-galactopyranoside (Fig. 1) derived from this species displayed antimetabolic activity against Melanoma A2058 cell line with 35 and 44% activity at 100 and 50 µg/mL concentrations, respectively [24]. (Martínez *et al.*, 2022). Andrade *et al.* (2018) reported that its carotenoid pigment viz. violaxanthin exhibited cytostatic activity against breast adenocarcinoma (MCF-7) at an active concentration of 40 µg/mL[3].




Fig. (1). Glycerol 1-(9Z,12Z,15Z-octadecatrienoate) 2-(4Z,7Z,10Z,13Z-hexadecatetraenoate)-3-O-β-D-galactopyranoside.

Tetraselmis suecica

The extracts of this species have shown rich α -tocopherol content and other vitamins and have shown cytotoxicity towards NCI-H460, MCF-7, HL-60, and tumor cells [25].

BLUE-GREEN ALGAE***Anabaena* sp.**

The extracts of *Anabaena* sp. M44, M30, and M27 strains triggered apoptosis and these extracts could serve as VGSC (Voltage-gated Na⁺ channel) inhibiting drugs with activities against cancer migration, invasion, and proliferation [26].

***Arthrospira platensis* (= *Spirulina platensis*)**

The polysaccharides isolated from this species showed antitumor activity [23]. Its phycocyanin possesses anti-cancer activities as shown in Table 1.

Table 1. Anticancer activity of the pigment phycocyanin on human cancer cells [27].

Cell Line	Phycocyanin Conc.	IC50
HCT116	50ug/mL	18.8ug/mL
HeLa	80;120ug/mL	1104ug/mL
HepG2	100uM	13uM
A549	50ug/mL	99.2ug/mL
HT-29	50; 200ug/mL	-
MCF-7	5.66ug/mL	5.66ug/mL
A375	40uM	-

***Calothrix* sp.**

Calothrixins A,B (Fig. 2) of this species also showed promising anticancer activity against human HeLa cancer cells with IC50 values of 40 and 350 nM, respectively [28].




Fig. (2). Calothrixins A,B.

CHAPTER 5**Anticancer Potential of Marine Sponges**

Abstract: This chapter deals with the anticancer activity of different chemical classes of compounds of marine sponges *viz.* alkaloids, terpenes, peptides and lipids. The mechanisms of action of the different compounds are also given.

Keywords: Anticancer compounds, Chemical classes of compounds, Marine sponges.

INTRODUCTION

Marine sponges (Phylum: Porifera), which are represented by about 15000 species are believed to be the oldest organisms surviving for more than 600 million years.

Among all marine organisms, these sponges are the richest source of marine bioactive compounds (ca. 5000) and are contributing to about 30% of all natural marine products identified so far. At least around 50 compounds of these sponges have the potential to be chemopreventive and/or anticancer agents.

The anticancer drug “Vidarabine” was first isolated by Bergmann and Feeney in the 1950s from a peculiar nucleoside isolated from a marine sponge, *Tethya crypta*. The chemical classes of these secondary metabolites such as sterols, alkaloids, terpenes, peptides, nucleosides, fatty acids, amino acid derivatives, and cyclic peptides are also well known for their cytotoxic, chemo-preventive and/or anticancer potential by different mechanisms, such as cell-cycle arrest, anti-inflammatory activity, apoptosis, *etc.* Considering the therapeutic importance of the marine sponge-derived bioactive metabolites, these organisms continue to be one of the most promising sources of new drug leads.

Anticancer Activity of Alkaloids of Marine Sponges***Aaptos aaptos***

Compound(s) and their mode(s) of action: Its benzonaphthyridine alkaloid, isoaptamine (Fig. 1) exhibited potent cytotoxic activity against breast cancer T-47D cells. Further, this compound showed autophagy by allowing the orderly

degradation (of unwanted components) and recycling of cellular components [137]. Furthermore, its compound aaptamine (Fig. 2) aids in inducing apoptosis of NT2 and HepG2 cell lines at a dose of 1-50 μM and 50-100 μM , respectively [9]. Its four new aaptamine derivatives have also been reported to display significant cytotoxicity against HL60, K562, MCF-7, KB, HepG2, and HT-29 cells, with IC_{50} values in the range of 0.03 to 8.5 μM [138].




Fig. (1). Isoaaptamine.




Fig. (2). Aaptamine.

Aaptos suberitoides

Compound(s) and their mode(s) of action: Among its bis-aaptamine alkaloids *viz.* suberitine A-D, suberitine B and D (Fig. 3) displayed potent cytotoxicity against P388 cell lines, with $\text{IC}(50)$ values of 1.8 and 3.5 μM , respectively [139]. Its aaptamine was found to induce apoptosis of MG63 and K562 cell lines at a dose of 30 $\mu\text{g}/\text{mL}$ and 20–100 μM respectively [9].




Fig. (3). Suberitine B, D.

***Aaptos* sp.**

Compound(s) and their mode(s) of action: Its demethyl(oxy)aaptamine (Fig. 4) and aaptamine induced apoptosis of THP-1 cell line at a concentration range of 10-25 μM [9]. Its demethyl(oxy)aaptamine (Fig. 4) and aaptamines were found to induce apoptosis of the THP-1 cell line at a dose e of 10-25 μM [9]. Further, its iso-aaptamine displayed anticancer activity against the P338 cancer cell line at an IC_{50} value of 0.28 $\mu\text{g/mL}$ [140].




Fig. (4). Demethyl (oxy) aaptamine.

Aplysina aerophoba

Compound(s) and their mode(s) of action: The brominated alkaloid, isofistularin-3 (Fig. 5) of this species induced apoptosis of Raji and U937 cell lines at a dose of 50 μM [9].




Fig. (5). Isofistularin-3.

Arenosclera brasiliensis

Compound(s) and their mode(s) of action: The tetracyclic alkylpiperidine alkaloids of this species *viz.* haliclonyclamine E (Fig. 6) and arenosclerin A- C (Figs. 7-9) displayed cytotoxicity against HL-60, L929, B16, and U138 cancer cell lines [141].

Anticancer Potential of Marine Cnidarians

Abstract: The anticancer potential of the marine organisms of the phylum: Cnidaria viz. medusae of Hydrozoa, Scyphozoa and Cubozoa; and soft, stony and black corals and sea anemones of Anthozoa are given in this chapter.

Keywords: Anthozoan soft corals, Anticancer potential, Cubozoan medusae, Hydrozoan medusae, Scyphozoan medusae, Stony and black corals, Sea anemones.

INTRODUCTION

Cnidarians are largely known to be largely responsible for the envenomations of humans during their fishing, and bathing in the marine environment, especially in tropical oceanic waters including Asia and Australia. Cnidarian stings are known to cause serious threats to human health by inducing local and systemic symptoms. However, these marine cnidarians have been reported to be a promising source of drug candidates in the development of new drugs or biomedical materials; for example, the vasoconstrictive compound and anaesthetic viz. palytoxin from the anthozoan species, *Palythoa toxica*; and prostaglandins (15R)-PGA2 derived from the gorgonian species viz. *Plaxaura homomalla* are well known. Further, in the recent decade, a considerable number of antioxidant and anticancer compounds have also been derived from these marine cnidarians and many of them are in clinical trials. This chapter deals with the anticancer compounds of the marine cnidarians species of and their venoms; and their mechanisms of action for pharmaceutical and therapeutic applications against various types of cancer.

Anticancer Compounds of Marine Hydrozoans (Phylum: Cnidaria; Class: Hydrozoa) and their Action Mechanisms

Abylopsis eschscholtzii

Its extract containing GFP-like proteins has been reported to emit bioluminescence, which is used in cancer therapy [172].

Aeginura Grimaldi, Aegina citrea, Colobonema sericeum and Arctapodema sp.

The extracts of these species possess polypeptides which displayed cytotoxicity against mouse leukemia L1210 cells with IC₅₀ values of 100,170,190 and 420 mg/ml, respectively [173,174].

Aequorea aequorea

The nematocyst extract of these species has shown cytotoxicity at an IC₅₀ of 76.6 × 10³ nematocysts/mL. Further, this extract has been reported to slow down the growth of cancer cells [174].

Chlorohydra viridissima

The extracts of this species produced toxicity in the human HEK293 (embryonic kidney) cell line [174].

Crossota rufobrunnea

The extract of this species possessing polypeptides displayed hemolytic effects at IC₅₀ of 100mg/ml [173].

Halecium muricatum and Halecium beanie

These species have been reported to yield Swiss lipids *viz.* 1-Tetradecyl-sn-glycero-3-phosphocholine and 1-O-hexadecyl-sn-glycero-3-phosphocholine. (Figs. 1-2). While the former compound displayed activity against the lung fibroblast cell line, the latter displayed anticancer effects against the human MCF-7 (breast carcinoma) cell line at a concentration of 100 µg/mL [175].




Fig. (1). 1-Tetradecyl -sn-glycero- 3-phosphocholine.




Fig. (2). 1-O- hexadecyl-sn- glycero-3- phosphocholine.

Halicreas minimum and Pantachogon Haeckel

The extracts of these species containing polypeptides displayed cytotoxicity against mouse leukemia L1210 cells with IC₅₀ values of 750 and 160mg/ml, respectively [173,174].

Macrorhynchia philippina

This species has yielded pyrroloiminoquinones *viz.* macrophilone A- G . Of these compounds, macrophilone A, C (Figs. 3-4) displayed potent and specific cytotoxic activity in the NCI 60 cancer cell line panel. Further, compound macrophilone A exhibited sub-micromolar cytotoxicity towards lung adenocarcinoma cells [5, 176].




Fig. (3). Macrophilone A.




Fig. (4). Macrophilone C.

Physalia physalis

The two promising toxins *viz.* PpV9.4 and PpV19.3 purified from this siphonophore have been reported to show cytotoxicity [174].

Thuiaria breifussi

The indole-oxazole-pyrrole alkaloids, breifussin C-D (Figs. 5-6) of this arctic hydrozoan species have been reported to possess cytotoxicity against several human cancer cell lines with IC₅₀ values below 10 μM [5].

CHAPTER 7**Anticancer Potential of Marine Bryozoans**

Abstract: This chapter deals with the anticancer and cytotoxic compounds of marine bryozoans and their mechanisms of action. Most of the anticancer compounds of these bryozoans were found to belong to the chemical classes alkaloids and lactones.

Keywords: Alkaloids, Anti cancer compounds, Cytotoxic compounds, Lactones, Marine bryozoans.

INTRODUCTION

The phylum Bryozoa includes filter-feeding, benthic invertebrates like moss animals, sea mats, or lace corals, which are found to be distributed in diverse marine habitats from the intertidal coastal areas to the deep sea. Most of the species of this phylum are colonial and are in different shapes like encrusting sheets to branched chains. These marine bryozoans are known to produce therapeutically important secondary metabolites of different chemical classes with various biological activities. The well known promising anticancer compound *viz.* bryostatin-1 derived from the marine bryozoan species *viz.* *Bugula neritina* was under investigation in Phase I/II clinical trials. However, the FDA (USA) has granted only orphan drug status to this compound in amalgamation with paclitaxel (a chemotherapy medication) for esophageal cancer as it has displayed minimal anti-tumor activity as a single agent. It is also worth mentioning here that only a total of about 250 new bioactive compounds have so far been derived and characterized from about 50 species of bryozoans although the number of marine bryozoan species is believed to exceed 8000. This is largely due to their taxonomic problems as most of them resemble seaweeds or members of other phyla like anthozoa or endoprocata. Another major constraint is the adequate supply of bioactive compounds from this organism as only a small amount of compounds are invariably collected from the collected larger quantities of species biomass. For example, it has been estimated that 13 tons of the marine bryozoan species *viz.* *Bugula neritina* needs to be harvested to obtain only 18 g of pure

bryostatin I. Further, collection problems do exist as about 50% of the marine bryozoan species have habitats deeper than 40 m, and about 30% of the species are found to be distributed below 700 m in depth [12].


Anticancer and Cytotoxic Metabolites of Marine Bryozoans

Marine bryozoan species are known to have alkaloids which are believed to be the most common and promising class of bioactive compounds used in the development of anticancer drugs. The anticancer and cytotoxic effects of marine bryozoan species possessing alkaloid compounds are given below [12].

Anticancer Alkaloid Compounds of Marine Bryozoans

Amathia convoluta

The alkaloid compounds *viz.*, convolutamide A–F derived from this species, convolutamide A, B have been reported to display cytotoxic effects against human KB (epidermoid carcinoma) cell line and murine leukemia (L-1210) cells at IC₅₀s of 2.8 and 4.8 μg/mL, respectively. Furthermore, oxindole alkaloid compounds *viz.* convolutamydine A–D; and β-phenylethylamine alkaloid compounds namely convolutamine A–G (Figs. 1-7) and lutamide A, C have also been isolated from this species. Among the convolutamydines, convolutamydine A displayed potent activity against human HL-60 (plomyelocytic leukemia) cells at doses of 0.1–25 μg/mL. Among the convolutamines, convolutamine A, C, and F showed inhibitory activity against adriamycin -resistant ADM/ P-388 with IC₅₀s of 7, 3, and 9.5 μg/mL; and against vincristine -resistant VCR/P-388 with IC₅₀s of 3, 1.4, and 8 μg/mL, respectively. Moreover, its convolutamine B and D exhibited antimitotic activity against P-388 with IC₅₀s of 4.8 and 8.6 μg/mL respectively; and convolutamine F acted against vincristine-resistant VJ300/ KB cell lines at an IC₅₀ of 9.6 μg/mL. Furthermore, its lutamide A and C showed inhibitory activity against VJ300/KB cells with IC₅₀s of 7.5 and 6.5 μg/mL respectively; and lutamide C acted against VCR/P-388 with an IC₅₀ value of 4.8 μg/mL.



Figs. (1-3). Convolutamine A-C.




Fig. (4). Convolutamine D.





Fig. (5). Convolutamine E.


Convolutamine: R1=Br. R2=CH₃; Convolutamine B: R1= H. R2= CH₃;
Convolutamine C; R1=Br. R2=H.



Figs. (6-7). Convolutamine F,G. (Convolutamine F: R1=H. R2=R3=Br; Convolutamine G: R1=R2=H. R3=Br.)

Amathia tortuosa

The alkaloids, convolutamines I–J (Figs. 8, 9) derived from this species exhibited potent activity against ATP competitive inhibitors.



Figs. (8-9). Convolutamines I–J.

CHAPTER 8**Anticancer Potential of Marine Shellfish**

Abstract: This topic describes the anticancer metabolites of the components of marine shellfish such as crustaceans (shrimp, lobsters, crayfish, and crabs), marine molluscs *viz.* bivalves (clams, oysters, *etc.*), gastropods (snails, slugs, *etc.*) and cephalopods (squids, octopuses, and cuttlefish). Among the bioactive compounds of marine molluscs, the anti-proliferative and cytotoxic compounds accounted for 12 and 36%. Among echinoderms, the asteroids (starfish), echinoids (sea urchins) and holothuroids (sea cucumbers) are found to be pharmaceutically important. Among the bioactive metabolites of echinoderms, the cytotoxic or anti-proliferative metabolites accounted for 38%.

Keywords: Cephalopod ink, Echinoderms, Marine shellfish, Marine crustaceans, Marine molluscs.

INTRODUCTION

The fisheries term “shellfish” includes exoskeleton-bearing marine invertebrates such as the fauna of molluscs, crustaceans, and echinoderms. Marine crustaceans include members of shrimp, lobsters, crayfish, and crabs; marine molluscs have their representatives from bivalves (clams, oysters, *etc.*), gastropods (snails, slugs, *etc.*) and cephalopods (squids, octopuses, and cuttlefish). Among the marine shellfish, the gastropods and echinoderms have been reported to possess rich anticancer compounds. The ink of cephalopods which are highly advanced and organized molluscs possesses many health benefits and as a traditional medicine in China, Greece and Rome. This cephalopod ink offers vast scope to develop new drugs. Among bivalves and gastropods, only a very small number of species have been examined for their bioactive compounds. A total of 255 new bioactive metabolites have been described from the marine molluscan fauna between 2010 and 2019 and the cytotoxic and anti-proliferative compounds have been reported to account for 36% and 12% respectively. Furthermore, the peptides, sterols terpenes, and polyketides were found to be 31, 8, 24, and 15% respectively; and other chemical classes including polyphenols were found to be 22% of the compounds. The echinoderm fauna, which are found only in the marine

environments, constitute about 7000 species and inhabit the benthic ocean floors in their adult stages. The different groups of the phylum Echinodermata are sea stars and starfish (Class: Asteroidea); brittle stars (Class: Ophiuroidea); sea urchins (Class: Echinoidea); and sea cucumbers (Class: Holothuroidea). These echinoderms have been reported to produce largely glycosylated compounds including steroids, glycolipids and saponins. Among echinoderms, the members of Asteroidea, Echinoidea and Holothuroidea are known to produce promising anti-tumor compounds, which amount to 38%. Starfish-derived compounds include mainly asterosaponins and polyhydroxy steroid glycosides with promising anticancer, anti-inflammatory agents, neuritogenic, and antimicrobial properties. Sea urchins are known for their antimicrobial compounds such as peptides including short cationic peptides with positively-charged amino acid residues like strongylocins, centrocin 1 and 2 or their analogues and paracentrin 1. Further, sea urchin pigments, which are found in their test spines, coelomocytes or gonads yield powerful antioxidant compounds. The body wall of sea cucumbers contains mainly polysaccharides and collagen, which are known to display anticancer, anti-hypertensive, anti-angiogenic, anti-inflammatory, anti-diabetic, anticoagulation, antimicrobial, antioxidant, and anti-osteoclastogenic properties. Further, these animals contain saponins, cerebrosides and gangliosides with numerous biological activities. Overall, this phylum exhibits a great variety of bioactive compounds *viz.* cytotoxic or anti-proliferative (38%); anticoagulant (16%); antimicrobial (9%), and antioxidant (7%) [5, 183].

MARINE CRUSTACEANS

Shrimps

Litopenaeus vannamei

The peptides of this species have been reported to induce apoptosis and anticancer activities in the HCT-116 colon cancer cell line. There was an increased apoptosis rate of cells treated with the gradual and mix peptides of this species with percentage values of 75.5% and 76%, respectively [184].

Penaeus indicus

This Indian white shrimp exhibited anticancer activity against H460 and HEP-2 (human lung and liver cancer) cell lines [185].

Lobster and Shrimp Shell Wastes

The peptide fractions of the lobster and shrimp wastes have been reported to significantly inhibit the growth of both colon and liver cancer cells by 60% [186].

Marine Crabs

Calappa calappa

The hemolymph of this species has shown high anticancer activity on Vero cells. About Fifty percent (50%) IC₅₀ of cytotoxicity was observed at the concentrations of 75, 100, 95, 100 and 95 µg mL⁻¹ in MCF-7, HepG2, A549, Rhabdomyosarcoma, and HT-29 cell lines, respectively [187].

Chionoecetes opilio

At a pH of 6 and concentration of 188 g/mL, the KCl₂ run 1 fraction of this species showed a mortality of 83.9%, 86.9%, 57%, and 93.2% for A549, BT549, HCT15, and PC3 cells, respectively. Further, at a concentration of 190 g/mL, its KCl₂ run 2 fractions, exhibited mortality on A549 and PC3 cancerous cell lines with percentage values of 74% and 100% respectively [188].

Portunus segnis

Its extracts exhibited antimitotic effects against human HT-29 (colorectal adenocarcinoma) cell line. The IC₅₀ values recorded for the aqueous extracts were found to be 44.33, 31.97, and 19.38 µg/mL during 24, 48 and 72 hrs respectively; the corresponding values for the hexane extracts were 35.27, 25.07 and 19.25 µg/mL; 26.63, 15.13, and 10.12 µg/mL for the butanol extracts; and for ethyl acetate 48.14, 34.63 and 22.86 µg/mL respectively [19].

Serratia marcescens

The microbial pigment prodigiosin of the wastes of this animal has shown anti-tumor property by inducing apoptosis in human cervical carcinoma cancer (HeLa) cell lines in a dose-dependent manner with an iC₅₀ range of 680-700nM [189].

Chitosan Derived from Crab Shell Wastes

The chitosan (Fig. 1) derived from the crab shell wastes has been reported to show anticancer effects. The chitosan-based nanoparticles conjugated with glutaraldehyde (ChNP-GA) were found to significantly reduce the viability of HCT-116 cancer cells in a dose-dependent manner besides reducing the cell morphology of the cancer cells (nuclear condensation and nuclear augmentation) of the cancer cells. Further, the combined treatment of chitosan-based hydrogel and cancer drug, PTX decreased the viability of SKOV3, one of the human ovarian tumor cell lines, by 3.33 fold. Furthermore, the glycyrrhetic acid-modified chitosan (GACTS)-based 5-FU (anti-cancer drug 5-fluorouracil) nanoparticle showed inhibitory activity on SMMC-7721 and SW480 cell lines and

CHAPTER 9**Anticancer Potential of Marine Chordates**

Abstract: The anticancer compounds of tunicates and marine fishes *viz.* elasmobranchs and teleosts are dealt with in this chapter.

Keywords: Anticancer compounds, Elasmobranchs, Tunicates, Teleosts.

INTRODUCTION


Tunicates (Subphylum: Tunicata) are the marine invertebrate chordates and they earn the common name due to the presence of a cellulose compound *viz.* tunicin in their external layer of the body. Members of tunicates are benthic and sessile (Asciacea) or pelagic (Thaliacea or Larvacea). Among the tunicates, the ascidians or sea squirts which constitute more than 2300 species of the total tunicates species numbering about 3000. The bioactive compounds of tunicates are represented by alkaloids, (50%) polyketides (37%) and peptides (13%). Among the members of tunicates, the ascidians have been reported to possess promising anticancer compounds, which amount to 58% of their total bioactive metabolites. It is worthy of mention here that three of the anticancer compounds of these ascidians have already entered the clinical trials [5]. Among the marine fishes, the protein hydrolysates of certain species are a promising source of active biopeptides, which possess anticancer activity on several cell lines. The small protein syngnathids derived from the whole body of *Syngnathus arcus* was found to possess anticancer activity of human lung adenocarcinoma (A-549) and lymphoblastic leukaemia (CCRF-CEM) cell lines [220].

Tunicates

The anticancer compounds of marine ascidians (Tunicates; Asciacea) and their mechanisms of action are given below [221].

Aplidium altarium


The tyrosine derivatives, botryllamides K, L (Figs. 1-2) isolated from this species exhibited weak cytotoxicity against MCF-7 breast cancer cell line with IC50 values of 74, and 91 μM respectively; and against H460-lung cancer cell line with IC50s of 91 and 89 μM , respectively.




Figs. (1-2). Botryllamides K, L.

Aplidium caelestis

The quinoline carboxylic acids *viz.* caelestines A–D (Figs. 3-6) of this species exhibited weak cytotoxicity against MCF-7 breast adenocarcinoma cancer cells with IC50s of 39, 49, 40, and 38 μM respectively; NFF (neonatal foreskin fibroblasts) with 57, 66, 58, and 68 μM respectively ; and against MM96L melanoma cell line with 62, 69, 54, and 52 μM ; respectively.



Figs. (3-4). Caelestine A,B.




Figs. (5-6). Caelestine C,D.

Aplidium conicum


The alkane derivatives, conicaquinone A,B (Figs. 7-8) of this species showed significant cytotoxic activity against C6 (rat glioma) cells with IC₅₀s of 2.1 and 5 $\mu\text{g/mL}$ respectively.

Furthermore, the prenylated benzoquinones, thiaplidiaquinone A, B (Figs. 9-10) displayed potent cytotoxicity against human leukemia T Jurkat cells with an IC₅₀ value of 3 μM . Furthermore, the synthetic analogue aplidinone A Fig. (11) of this species reported cytotoxicity and pro-apoptotic activity against kidney cancer 293T and human lung adenocarcinoma A549 cell lines with IC₅₀ values of 8.7 and 13 μM , respectively. Aplidinone A has also been reported to potentially inhibit the activation of NF- κB (nuclear factor) pathway in human T-cell acute lymphoblastic leukemia cell line. It has also been reported that its meroterpenes *viz.* conithiaquinone A,B (Figs. 12-13) displayed significant effects on the growth and viability of cells and conithiaquinone A exhibited moderate cytotoxic activity on human breast cancer cell line with an IC₅₀ value of 44.5 μM .



Figs. (7-8). Conicaquinone : X= SO₂, Y=NH.

Fig. (8). Conicaquinone: X= NH, Y=SO₂.



Figs. (9-10). Thiaplidiaquinone A, B.




Fig. (11). Aplidinone A.

REFERENCES

- [1] Khalifa SAM, Elias N, Farag MA, *et al.* Marine Natural Products: A Source of Novel Anticancer Drugs. *Mar Drugs* 2019; 17(9): 491. [http://dx.doi.org/ 10.3390/md17090491] [PMID: 31443597]
- [2] Barreca M, Spanò V, Montalbano A, *et al.* Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. *Mar Drugs* 2020; 18(12): 619. [http://dx.doi.org/ 10.3390/md18120619] [PMID: 33291602]
- [3] Martínez Andrade K, Lauritano C, Romano G, Ianora A. Marine Microalgae with Anti-Cancer Properties. *Mar Drugs* 2018; 16(5): 165. [http://dx.doi.org/ 10.3390/md16050165] [PMID: 29762545]
- [4] Zuo W, Kwok HF. Development of Marine-Derived Compounds for Cancer Therapy 2021. <https://pubmed.ncbi.nlm.nih.gov/34203870/> [http://dx.doi.org/ 10.3390/md19060342]
- [5] Romano G, Almeida M, Varela Coelho A, *et al.* Biomaterials and Bioactive Natural Products from Marine Invertebrates: From Basic Research to Innovative Applications. *Mar Drugs* 2022; 20(4): 219. [http://dx.doi.org/ 10.3390/md20040219] [PMID: 35447892]
- [6] Karthikeyan A, Joseph A, Nair BG. Promising bioactive compounds from the marine environment and their potential effects on various diseases. *J Genet Eng Biotechnol* 2022; 20(1): 14. [http://dx.doi.org/ 10.1186/s43141-021-00290-4] [PMID: 35080679]
- [7] Dayanidhi DL. + 13. Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds. *Front Mar Sci* 2021; 7. <https://www.frontiersin.org/articles/10.3389/fmars.2020.614766/full>
- [8] Das G, Gouda S, Mohanta YK, Patra JK. Mangrove plants : A potential source of drugs. *Indian J Mar GeoSci* 2015; 44(5): 666-72. <http://www.niscair.res.in/jinfo/ijms/ijms-forthcoming-articles/BKP-IJMS-PR-May%202015/MS%202501%20Edited.pdf>
- [9] Calcabrini C, Catanzaro E, Bishayee A, Turrini E, Fimognari C. Marine Sponge Natural Products with Anticancer Potential: An Updated Review. *Mar Drugs* 2017; 15(10): 310. [http://dx.doi.org/ 10.3390/md15100310] [PMID: 29027954]
- [10] Rocha J, Peixe L. Cnidarians as a source of new marine bioactive compounds- -an overview of the last decade and future steps for bioprospecting. *Mar Drugs* 2011; 9(10): 1860-86. <https://pubmed.ncbi.nlm.nih.gov/22073000/> [PMID: 22073000]
- [11] Oliveira CS, Caldeira CAS, Diniz-Sousa R, *et al.* Pharmacological characterization of cnidarian extracts from the Caribbean Sea: evaluation of anti-snake venom and antitumor properties. *J Venom Anim Toxins Incl Trop Dis* 2018; 24(1): 22. [http://dx.doi.org/10.1186/s40409-018-0161-z] [PMID: 30181737]
- [12] Figuerola B, Avila C. The Phylum Bryozoa as a Promising Source of Anticancer Drugs. *Mar Drugs* 2019; 17(8): 477. [http://dx.doi.org/10.3390/md17080477] [PMID: 31426556]
- [13] Sima P, Vetvicka V. Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata. *World J Clin Oncol* 2011; 2(11): 362-6. [http://dx.doi.org/10.5306/wjco.v2.i11.362] [PMID: 22087434]
- [14] Patil P, Sahu BK, Panigrahy RC. Marine Molluscs as a Potential Drug Cabinet: An Overview. *Indian J Geo-Mar Sci* 2015; 44(7): 461-70. [[https://nopr.niscair.res.in/bitstream/123456789/34841/1/IJMS%2044\(7\)%20961-970.pdf](https://nopr.niscair.res.in/bitstream/123456789/34841/1/IJMS%2044(7)%20961-970.pdf)].

- [15] Santhanam R, Ramesh S. *Biology and Ecology of Pharmaceutical Marine Tunicates*, (Series: Biology and Ecology of Pharmaceutical Marine Life) CRC Press. USA: Taylor & Francis 2019. [http://dx.doi.org/10.1201/9780429321788]
- [16] Erwin PM, López-Legentil S, Schuhmann PW. The pharmaceutical value of marine biodiversity for anti-cancer drug discovery. *Ecol Econ* 2010; 70(2): 445-51. [http://dx.doi.org/10.1016/j.ecolecon.2010.09.030]
- [17] Saeed AFUH, Su J, Ouyang S. Marine-derived drugs: Recent advances in cancer therapy and immune signaling. *Biomed Pharmacother* 2021; 134. <https://pubmed.ncbi.nlm.nih.gov/33341044/> [PMID: 33341044]
- [18] Santaniello G, Nebbioso A, Altucci L, Conte M. Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets. *Mar Drugs* 2022; 21(1): 24. [http://dx.doi.org/10.3390/md21010024] [PMID: 36662197]
- [19] Han N, Li J, Li X. Natural Marine Products: Anti-Colorectal Cancer *In Vitro* and *In Vivo*. *Mar Drugs* 2022; 20(6): 349. [http://dx.doi.org/10.3390/md20060349] [PMID: 35736152]
- [20] Dyshlovoy SA, Honecker F. Marine Compounds and Cancer: Updates 2022. *Mar Drugs* 2022; 20(12): 759. [http://dx.doi.org/10.3390/md20120759] [PMID: 36547906]
- [21] Pelay-Gimeno M, García-Ramos Y, Jesús Martín M, *et al.* The first total synthesis of the cyclodepsipeptide pipecolidepsin A. *Nat Commun* 2013; 4(1): 2352. [http://dx.doi.org/10.1038/ncomms3352] [PMID: 23989475]
- [22] Martín MJ, Rodríguez-Acebes R, García-Ramos Y, *et al.* Stellatolides, a new cyclodepsipeptide family from the sponge *Ecionemia acervus*: isolation, solid-phase total synthesis, and full structural assignment of stellatolide A. *J Am Chem Soc* 2014; 136(18): 6754-62. [http://dx.doi.org/10.1021/ja502744a] [PMID: 24725163]
- [23] Wu J, Gu X, Yang D, *et al.* Bioactive substances and potentiality of marine microalgae. *Food Sci Nutr* 2021; 9(9): 5279-92. [http://dx.doi.org/10.1002/fsn3.2471] [PMID: 34532034]
- [24] Martínez KA, Saide A, Crespo G, *et al.* Promising Antiproliferative Compound From the Green Microalga *Dunaliella tertiolecta* Against Human Cancer Cells. *Front Mar Sci* 2022; 9: 778108. <https://www.researchgate.net/publication/35867473> [http://dx.doi.org/10.3389/fmars.2022.778108]
- [25] https://en.wikipedia.org/wiki/Tetrasselmis_suecica
- [26] Pradhan B, Ki JS. Phytoplankton Toxins and Their Potential Therapeutic Applications: A Journey toward the Quest for Potent Pharmaceuticals. *Mar Drugs* 2022; 20(4): 271. [http://dx.doi.org/10.3390/md20040271] [PMID: 35447944]
- [27] Braune S, Krüger-Genge A, Kammerer S, Jung F, Küpper JH. Phycocyanin from *Arthrospira platensis* as Potential Anti-Cancer Drug: Review of *In Vitro* and *In Vivo* Studies. *Life (Basel)* 2021; 11(2): 91. [http://dx.doi.org/10.3390/life11020091] [PMID: 33513794]
- [28] https://accedacris.ulpgc.es/bitstream/10553/74363/2/0767079_00000_0000.pdf
- [29] Keller L. + 12. Tutuilamides A-C: Vinyl-Chloride Containing Cyclodepsipeptides from Two Marine Cyanobacteria *Schizothrix* sp. and *Coleofasciculus* sp. with Potent Elastase Inhibitory Properties. *ACS Chem Biol* 2020; 15(3): 751-7. [http://dx.doi.org/10.1021/acscchembio.9b00992] [PMID: 31935054]
- [30] Leão PN, Costa M, Ramos V, *et al.* Antitumor activity of hierridin B, a cyanobacterial secondary metabolite found in both filamentous and unicellular marine strains. *PLoS One* 2013; 8(7): e69562.

- [http://dx.doi.org/10.1371/journal.pone.0069562] [PMID: 23922738]
- [31] Khalifa SAM, Shedid ES, Saied EM, *et al.* Cyanobacteria—From the Oceans to the Potential Biotechnological and Biomedical Applications. *Mar Drugs* 2021; 19(5): 241. [http://dx.doi.org/10.3390/md19050241] [PMID: 33923369]
- [32] Costa M, Garcia M, Costa-Rodrigues J, *et al.* Exploring bioactive properties of marine cyanobacteria isolated from the Portuguese coast: high potential as a source of anticancer compounds. *Mar Drugs* 2013; 12(1): 98-114. [http://dx.doi.org/10.3390/md12010098] [PMID: 24384871]
- [33] Kurisawa N, Iwasaki A, Jeelani G, Nozaki T, Suenaga K, Iheyamides A-C. Iheyamides A-C, Antitrypanosomal Linear Peptides Isolated from a Marine *Dapis* sp. Cyanobacterium. *J Nat Prod* 2020; 83(5): 1684-90. [http://dx.doi.org/10.1021/acs.jnatprod.0c00250] [PMID: 32352773]
- [34] https://accedacris.ulpgc.es/bitstream/10553/74363/2/0767079_00000_0000.pdf
- [35] Konstantinou D, Voultziadou E, Panteris E, Zervou SK, Hiskia A, Gkelis S. *Leptothoe*, a new genus of marine cyanobacteria (Synechococcales) and three new species associated with sponges from the Aegean Sea. *J Phycol* 2019; 55(4): 882-97. [http://dx.doi.org/10.1111/jpy.12866] [PMID: 31001838]
- [36] Liu L, Rein KS. New peptides isolated from *Lyngbya* species: a review. *Mar Drugs* 2010; 8(6): 1817-37. [http://dx.doi.org/10.3390/md8061817] [PMID: 20631872]
- [37] Gunasekera SP, Ritson-Williams R, Paul VJ. Carriebowmide, a new cyclodepsipeptide from the marine cyanobacterium *Lyngbya polychroa*. *J Nat Prod* 2008; 71(12): 2060-3. [http://dx.doi.org/10.1021/np800453t] [PMID: 19007282]
- [38] Thornburg CC, Thimmaiah M, Shaala LA, *et al.* Cyclic depsipeptides, grassypeptolides D and E and Ibu-epidemethoxylyngbyastatin 3, from a Red Sea *Leptolyngbya* cyanobacterium. *J Nat Prod* 2011; 74(8): 1677-85. [http://dx.doi.org/10.1021/np200270d] [PMID: 21806012]
- [39] Tang HF, Yi Y-H, Yao XS, Xu QZ, Zhang SY, Lin HW. Bioactive steroids from the brown Alga *Sargassum carpophyllum*. *J Asian Nat Prod Res* 2002; 4(2): 95-101. [http://dx.doi.org/10.1080/10286020290027362] [PMID: 12067165]
- [40] https://accedacris.ulpgc.es/bitstream/10553/74363/2/0767079_00000_0000.pdf
- [41] Thornburg CC, Cowley ES, Sikorska J, *et al.* Apratoxin H and apratoxin A sulfoxide from the Red Sea cyanobacterium *Moorea producens*. *J Nat Prod* 2013; 76(9): 1781-8. [http://dx.doi.org/10.1021/np4004992] [PMID: 24016099]
- [42] Sousa ML, Preto M, Vasconcelos V, Linder S, Urbatzka R. Antiproliferative Effects of the Natural Oxadiazine Nocuolin A Are Associated With Impairment of Mitochondrial Oxidative Phosphorylation. *Front Oncol* 2019; 9: 224. [http://dx.doi.org/10.3389/fonc.2019.00224] [PMID: 31001482]
- [43] Li Z, Guo M. Healthy efficacy of *Nostoc commune* Vaucher. *Oncotarget* 2018; 9(18): 14669-79. [http://dx.doi.org/10.18632/oncotarget.23620] [PMID: 29581873]
- [44] Wali AF, Majid S, Rasool S, *et al.* Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer. *Saudi Pharm J* 2019; 27(6): 767-77. [http://dx.doi.org/10.1016/j.jsps.2019.04.013] [PMID: 31516319]
- [45] Martins J, Campos A, Leão PN, Vasconcelos V. Investigation of HDAC and 20S Proteasome Inhibitors from Cyanobacteria p.117. *Mar Drugs* 2020; 18. [Synopsis].
- [46] Sumimoto S, Kobayashi M, Sato R, *et al.* Minnamide A, a Linear Lipopeptide from the Marine Cyanobacterium *Okeania hirsuta*. *Org Lett* 2019; 21(4): 1187-90.

- [http://dx.doi.org/10.1021/acs.orglett.9b00135] [PMID: 30730753]
- [47] Nweze JA, Mbaaji FN, Huang G, *et al.* Antibiotics Development and the Potentials of Marine-Derived Compounds to Stem the Tide of Multidrug-Resistant Pathogenic Bacteria, Fungi, and Protozoa. *Mar Drugs* 2020; 18(3): 145. [http://dx.doi.org/10.3390/md18030145] [PMID: 32121196]
- [48] Sueyoshi K, Kaneda M, Sumimoto S, *et al.* Odoamide, a cytotoxic cyclodepsipeptide from the marine cyanobacterium *Okeania* sp. *Tetrahedron* 2016; 72(35): 5472-8. [https://doi.org/10.1016/j.tet.2016.07.031]. [http://dx.doi.org/10.1016/j.tet.2016.07.031]
- [49] Petitbois JG, Casalme LO, Lopez JAV, *et al.* Serinolamides and Lyngbyabellins from an *Okeania* sp. Cyanobacterium Collected from the Red Sea. *J Nat Prod* 2017; 80(10): 2708-15. [http://dx.doi.org/10.1021/acs.jnatprod.7b00449] [PMID: 29019684]
- [50] Harrigan GG, Yoshida WY, Moore RE, *et al.* Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from *Lyngbya majuscula/Schizothrix calcicola* cyanobacterial assemblages. *J Nat Prod* 1998; 61(10): 1221-5. [http://dx.doi.org/10.1021/np9801211] [PMID: 9784156]
- [51] <https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/symploca>
- [52] Phyto MY, Ding CYG, Goh HC, *et al.* Trikoramide A, a Prenylated Cyanobactin from the Marine Cyanobacterium *Symploca hydnooides*. *J Nat Prod* 2019; 82(12): 3482-8. [http://dx.doi.org/10.1021/acs.jnatprod.9b00675] [PMID: 31763840]
- [53] Ma YP, Ding CYG, Ong JFM, Tan LT. Isolation and Structure Determination of Trikoramide A from the Marine Cyanobacterium *Symploca* sp. 99. *Mar Drugs* 2020; 18. [Synopsis].
- [54] https://accedacris.ulpgc.es/bitstream/10553/74363/2/0767079_00000_0000.pdf
- [55] Williams PG, Yoshida WY, Moore RE, Paul VJ. Tasiptepsins A and B: new cytotoxic depsipeptides from the marine cyanobacterium *Symploca* sp. *J Nat Prod* 2003; 66(5): 620-4. [http://dx.doi.org/10.1021/np020582t] [PMID: 12762794]
- [56] Khan MI, Shin JH, Kim JD. The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry for biofuels, feed, and other products. *Microb Cell Fact* 2018; 17(1): 36. [http://dx.doi.org/10.1186/s12934-018-0879-x] [PMID: 29506528]
- [57] Matos J, Cardoso C, Gomes A, *et al.* Bioprospection of *Isochrysis galbana* and its potential as a nutraceutical. *Food Funct* 2019; 10(11): 7333-42. [http://dx.doi.org/10.1039/C9FO01364D] [PMID: 31646314]
- [58] Mishra N, Mishra N. Exploring the biologically active metabolites of *Isochrysis galbana* in pharmaceutical interest: An overview. *IJPSR* 2018; 9: 2162-74. [https://ijpsr.com/articles/].
- [59] <https://en.wikipedia.org/wiki/Prymnesin-2>
- [60] Hussein HA, Abdullah MA. Anticancer Compounds Derived from Marine Diatoms. *Mar Drugs* 2020; 18(7): 356. [http://dx.doi.org/10.3390/md18070356] [PMID: 32660006]
- [61] Gastineau R, Turcotte F, Pouvreau JB, *et al.* Marennine, promising blue pigments from a widespread *Haslea* diatom species complex. *Mar Drugs* 2014; 12(6): 3161-89. [http://dx.doi.org/10.3390/md12063161] [PMID: 24879542]
- [62] Luo X, Su P, Zhang W. Advances in Microalgae-Derived Phytosterols for Functional Food and Pharmaceutical Applications. *Mar Drugs* 2015; 13(7): 4231-54. [http://dx.doi.org/10.3390/md13074231] [PMID: 26184233]
- [63] Kim YS, Li XF, Kang KH, Ryu B, Kim SK. Stigmasterol isolated from marine microalgae *Navicula incerta* induces apoptosis in human hepatoma HepG2 cells. *BMB Rep* 2014; 47(8): 433-8.

- [http://dx.doi.org/10.5483/BMBRep.2014.47.8.153] [PMID: 24286323]
- [64] Riccio G, Lauritano C. Microalgae with Immunomodulatory Activities. *Mar Drugs* 2019; 18(1): 2. [http://dx.doi.org/10.3390/md18010002] [PMID: 31861368]
- [65] Gabed N, Verret F, Peticca A, *et al.* What Was Old Is New Again: The Pennate Diatom *Haslea ostrearia* (Gaillon) Simonsen in the Multi-Omic Age. *Mar Drugs* 2022; 20(4): 234. [http://dx.doi.org/10.3390/md20040234] [PMID: 35447907]
- [66] de Vera C, Díaz Crespín G, Hernández Daranas A, *et al.* Marine Microalgae: Promising Source for New Bioactive Compounds. *Mar Drugs* 2018; 16(9): 317. [http://dx.doi.org/10.3390/md16090317] [PMID: 30200664]
- [67] Sansone C, Galasso C, Orefice I, *et al.* The green microalga *Tetraselmis suecica* reduces oxidative stress and induces repairing mechanisms in human cells. *Sci Rep* 2017; 7(1): 41215. [http://dx.doi.org/10.1038/srep41215] [PMID: 28117410]
- [68] Munday R, Quilliam MA, LeBlanc P, *et al.* Investigations into the toxicology of spirolides, a group of marine phycotoxins. *Toxins (Basel)* 2011; 4(1): 1-14. [http://dx.doi.org/10.3390/toxins4010001] [PMID: 22347619]
- [69] Martínez KA, Lauritano C, Druka D, *et al.* Amphidinol 22, a New Cytotoxic and Antifungal Amphidinol from the Dinoflagellate *Amphidinium carterae*. *Mar Drugs* 2019; 17(7): 385. [http://dx.doi.org/10.3390/md17070385] [PMID: 31252576]
- [70] Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. *J Pharmacol Pharmacother* 2016; 7(2): 62-71. [http://dx.doi.org/10.4103/0976-500X.184769] [PMID: 27440950]
- [71] Mejía-Camacho AL, Durán-Riveroll LM, Cembella AD. Toxicity Bioassay and Cytotoxic Effects of the Benthic Marine Dinoflagellate *Amphidinium operculatum*. *J Xenobiot* 2021; 11(2): 33-45. [http://dx.doi.org/10.3390/jox11020003] [PMID: 33925574]
- [72] Bauer I, Maranda L, Young KA, *et al.* Isolation and Structure of Caribenolide I, a Highly Potent Antitumor Macrolide from a Cultured Free-Swimming Caribbean Dinoflagellate, *Amphidinium* sp. S1-36-5. *J Org Chem* 1995; 60(4): 1084-6. [https://doi.org/10.1021/jo00109a050]. [http://dx.doi.org/10.1021/jo00109a050]
- [73] Kumagai K, Minamida M, Akakabe M, *et al.* Amphirionin-2, a novel linear polyketide with potent cytotoxic activity from a marine dinoflagellate *Amphidinium* species. *Bioorg Med Chem Lett* 2015; 25(3): 635-8. [http://dx.doi.org/10.1016/j.bmcl.2014.12.003] [PMID: 25534608]
- [74] Washida K, Koyama T, Yamada K, Kita M, Uemura D. Karatungiols A and B, two novel antimicrobial polyol compounds, from the symbiotic marine dinoflagellate *Amphidinium* sp. *Tetrahedron Lett* 2006; 47(15): 2521-5. [https://doi.org/10.1016/j.tetlet.2006.02.045]. [http://dx.doi.org/10.1016/j.tetlet.2006.02.045]
- [75] Akakabe M, Kumagai K, Tsuda M, *et al.* Iriomoteolide-13a, a cytotoxic 22-membered macrolide from a marine dinoflagellate *Amphidinium* species. *Tetrahedron* 2014; 70(18): 2962-5. [https://doi.org/10.1016/j.tet.2014.03.025]. [http://dx.doi.org/10.1016/j.tet.2014.03.025]
- [76] Iwai T, Kubota T, Kobayashi J. Absolute configuration of amphidinin A. *J Nat Prod* 2014; 77(6): 1541-4. [http://dx.doi.org/10.1021/np5003065] [PMID: 24836179]
- [77] Ferrara L. Dinoflagellates Important Marine Producers of Natural Bio-Compounds with High Biotechnological and Pharmacological Potential. *Journal of Food Chemistry & Nanotechnology* 2020; 6(3): 138-49. [DOI:10.17756/jfcn.2020-095]. [http://dx.doi.org/10.17756/jfcn.2020-095]
- [78] Camacho F, Macedo A, Malcata F. Potential Industrial Applications and Commercialization of

- Microalgae in the Functional Food and Feed Industries: A Short Review. *Mar Drugs* 2019; 17(6): 312. [http://dx.doi.org/10.3390/md17060312] [PMID: 31141887]
- [79] Vogelstein B, Sur S, Prives C. p53: The Most Frequently Altered Gene in Human Cancers. *New Educator* 2010; 3: 6. [https://www.nature.com/scitable/topicpage/p53-the-most-frequently-altered-gene-in-14192717/#(IARCTP53database)].
- [80] Espiña B, Rubiolo JA. Marine toxins and the cytoskeleton: pectenotoxins, unusual macrolides that disrupt actin. *FEBS J* 2008; 275(24): 6082-8. [http://dx.doi.org/10.1111/j.1742-4658.2008.06714.x] [PMID: 19016860]
- [81] Reguera B, Riobó P, Rodríguez F, *et al.* Dinophysis toxins: causative organisms, distribution and fate in shellfish. *Mar Drugs* 2014; 12(1): 394-461. [http://dx.doi.org/10.3390/md12010394] [PMID: 24447996]
- [82] Kim GY, Kim WJ, Choi YH. Pectenotoxin-2 from marine sponges: a potential anti-cancer agent-a review. *Mar Drugs* 2011; 9(11): 2176-87. [http://dx.doi.org/10.3390/md9112176] [PMID: 22163180]
- [83] Soliño L, Sureda FX, Diogène J. Evaluation of okadaic acid, dinophysistoxin-1 and dinophysistoxin-2 toxicity on Neuro-2a, NG108-15 and MCF-7 cell lines. *Toxicol In Vitro* 2015; 29(1): 59-62. [http://dx.doi.org/10.1016/j.tiv.2014.09.002] [PMID: 25238672]
- [84] Ferron PJ, Hogeveen K, Fessard V, Hégarat L. Comparative analysis of the cytotoxic effects of okadaic acid-group toxins on human intestinal cell lines. *Mar Drugs* 2014; 12(8): 4616-34. [http://dx.doi.org/10.3390/md12084616] [PMID: 25196936]
- [85] Afonso TB, Costa MS, Rezende de Castro R, *et al.* Bartolosides E–K from a Marine Coccoid Cyanobacterium. *J Nat Prod* 2016; 79(10): 2504-13. [http://dx.doi.org/10.1021/acs.jnatprod.6b00351] [PMID: 27680198]
- [86] Kim D, Miyazaki Y, Nakashima T, *et al.* Cytotoxic action mode of a novel porphyrin derivative isolated from harmful red tide dinoflagellate *Heterocapsa circularisquama*. *J Biochem Mol Toxicol* 2008; 22(3): 158-65. [http://dx.doi.org/10.1002/jbt.20216] [PMID: 18561331]
- [87] Haguët Q, Bonnet A, Bérard J-B, *et al.* Antimelanoma activity of *Heterocapsa triquetra* pigments. *Algal Res* 2017; 25: 207-15. [https://doi.org/10.1016/j.algal.2017.04.034]. [http://dx.doi.org/10.1016/j.algal.2017.04.034]
- [88] Sugawara T, Yamashita K, Sakai S, *et al.* Induction of apoptosis in DLD-1 human colon cancer cells by peridinin isolated from the dinoflagellate, *Heterocapsa triquetra*. *Biosci Biotechnol Biochem* 2007; 71(4): 1069-72. [http://dx.doi.org/10.1271/bbb.60597] [PMID: 17420600]
- [89] Cai P, He S, Zhou C, *et al.* Two new karlotoxins found in *Karlodinium veneficum* (strain GM2) from the East China Sea. *Harmful Algae* 2016; 58: 66-73. [http://dx.doi.org/10.1016/j.hal.2016.08.001] [PMID: 28073460]
- [90] https://patents.google.com/patent/WO2015090591A1/en
- [91] Hwang BS, Yoon EY, Jeong EJ, Park J, Kim EH, Rho JR. Determination of the Absolute Configuration of Polyhydroxy Compound Ostreol B Isolated from the Dinoflagellate *Ostreopsis cf. ovata*. *J Org Chem* 2018; 83(1): 194-202. [http://dx.doi.org/10.1021/acs.joc.7b02569] [PMID: 29185743]
- [92] Pelin M, Forino M, Brovedani V, *et al.* Ovatoxin-a, A Palytoxin Analogue Isolated from *Ostreopsis cf. ovata* Fukuyo: Cytotoxic Activity and ELISA Detection. *Environ Sci Technol* 2016; 50(3): 1544-51. [http://dx.doi.org/10.1021/acs.est.5b04749] [PMID: 26714047]
- [93] https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/palytoxin
- [94] Camacho-Muñoz D, Praptiwi RA, Lawton LA, Edwards C. High Value Phycotoxins From the

- Dinoflagellate *Prorocentrum*. *Front Mar Sci* 2021; 8: 638739. [https://doi.org/10.3389/fmars.2021.638739]. [http://dx.doi.org/10.3389/fmars.2021.638739]
- [95] Sánchez-Suárez J, Garnica-Agudelo M, Villamil L, Díaz L, Coy-Barrera E. Bioactivity and Biotechnological Overview of Naturally Occurring Compounds from the Dinoflagellate Family Symbiodiniaceae: A Systematic Review. *ScientificWorldJournal* 2021; 1-10. [http://dx.doi.org/10.1155/2021/1983589] [PMID: 34955690]
- [96] Selwood AI, Wilkins AL, Munday R, Shi F, Rhodes LL, Holland PT. Portimine: a bioactive metabolite from the benthic dinoflagellate *Vulcanodinium rugosum*. *Tetrahedron Lett* 2013; 54(35): 4705-7. [https://doi.org/10.1016/j.tetlet.2013.06.098]. [http://dx.doi.org/10.1016/j.tetlet.2013.06.098]
- [97] Nézan E, Chomérat N. *Vulcanodinium rugosum* gen. et sp. nov. (Dinophyceae), un Nouveau Dinoflagellé Marin de la Côte Méditerranéenne Française. *Cryptogam, Algol* 2011; 32(1): 3-18. [https://sciencepress.mnhn.fr/en/periodiques/algologie/32/1/]. [http://dx.doi.org/10.7872/crya.v32.iss1.2011.003]
- [98] Geiger M, Desanglois G, Hogeveen K, *et al.* Cytotoxicity, fractionation and dereplication of extracts of the dinoflagellate *Vulcanodinium rugosum*, a producer of pinnatoxin G. *Mar Drugs* 2013; 11(9): 3350-71. [http://dx.doi.org/10.3390/md11093350] [PMID: 24002102]
- [99] Casas-Arrojo V, Decara J, de los Ángeles Arrojo-Agudo M, Pérez-Manríquez C, Abdala-Díaz R. Immunomodulatory, Antioxidant Activity and Cytotoxic Effect of Sulfated Polysaccharides from *Porphyridium cruentum*. (S.F.Gray) Nägeli. *Biomolecules* 2021; 11(4): 488. [http://dx.doi.org/10.3390/biom11040488] [PMID: 33805009]
- [100] Hamann MT. Technology evaluation: Kahalalide F, *PharmaMar*. *Curr Opin Mol Ther* 2004; 6(6): 657-65. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941207/]. [PMID: 15663330]. [PMID: 15663330]
- [101] Permatasari HK, Bulain S, Amar N, Rahma M. Anticancer Properties of *Caulerpa racemosa*: A Review Study. *Nutr Clín Diet Hosp* 2022; 42(3): 110-21. [https://doi.org/10.12873/423permatasari].
- [102] Cavas L, Baskin Y, Yurdakoc K, Olgun N. Antiproliferative and newly attributed apoptotic activities from an invasive marine alga: *Caulerpa racemosa* var. *cylindracea*. *J Exp Mar Biol Ecol* 2006; 339(1): 111-9. [https://avesis.deu.edu.tr/yayin/99d56092-c1a8-4d7f-bc79-8ad5c5d61d60/]. [http://dx.doi.org/10.1016/j.jembe.2006.07.019]
- [103] Tanna B, Yadav S, Mishra A. Anti-proliferative and ROS-inhibitory activities reveal the anticancer potential of *Caulerpa* species. *Mol Biol Rep* 2020; 47(10): 7403-11. [http://dx.doi.org/10.1007/s11033-020-05795-8] [PMID: 32990904]
- [104] Senthilkumar D, Jayanthi S. Partial characterization and anticancer activities of purified glycoprotein extracted from green seaweed *Codium decorticateum*. *J Funct Foods* 2016; 25: 323-32. [https://doi.org/10.1016/j.jff.2016.06.010]. [http://dx.doi.org/10.1016/j.jff.2016.06.010]
- [105] Zbakh H, Salhi G, Bochkov V, *et al.* Insights on the anti-inflammatory and antitumor activities of extracts from the marine green alga *Codium decorticateum*. *Eur J Integr Med* 2020; 37: 101170. [https://doi.org/10.1016/j.eujim.2020.101170]. [http://dx.doi.org/10.1016/j.eujim.2020.101170]
- [106] Mofeed J, Deyab M, Sabry AE, Ward F. *In Vitro* Anticancer Activity of Five Marine Seaweeds Extract From Egypt Against Human Breast and Colon Cancer Cell Lines. *Res Sq.* 2021. [https://doi.org/10.21203/rs.3.rs-462221/v1] [http://dx.doi.org/10.21203/rs.3.rs-462221/v1]
- [107] Lomartire S, Gonçalves AMM. An Overview of Potential Seaweed-Derived Bioactive Compounds for Pharmaceutical Applications. *Mar Drugs* 2022; 20(2): 141.

- [http://dx.doi.org/10.3390/md20020141] [PMID: 35200670]
- [108] Salindeho N, Nurkolis F, Gunawan WB, Handoko MN, Samtiya M, Muliadi RD. Anticancer and anticholesterol attributes of sea cucumbers: An opinion in terms of functional food applications. *Front Nutr* 2022; 9: 986986. [https://doi.org/10.3389/fnut.2022.986986]. [http://dx.doi.org/10.3389/fnut.2022.986986]
- [109] Cotas J, Pacheco D, Gonçalves AMM, Silva P, Carvalho LG, Pereira L. Seaweeds' nutraceutical and biomedical potential in cancer therapy: a concise review. *J Cancer Metastasis Treat* 2021; 7: 13. [http://hdl.handle.net/10316/100684]. [http://dx.doi.org/10.20517/2394-4722.2020.134]
- [110] Kim RK, Uddin N, Hyun JW, Kim C, Suh Y, Lee SJ. Novel anticancer activity of phloroglucinol against breast cancer stem-like cells. *Toxicol Appl Pharmacol* 2015; 286(3): 143-50. [http://dx.doi.org/10.1016/j.taap.2015.03.026] [PMID: 25843036]
- [111] Walter LO, Maiores MF, Silva LO, *et al.* Involvement of the NF- κ B and PI3K /Akt/ mTOR pathways in cell death triggered by stypoldione, an o-quinone isolated from the brown algae *Styopodium zonale*. *Environ Toxicol* 2022; 37(6): 1297-309. [http://dx.doi.org/10.1002/tox.23484] [PMID: 35128807]
- [112] Lins KOAL, Bezerra DP, Alves APNN, *et al.* Antitumor properties of a sulfated polysaccharide from the red seaweed *Champia feldmannii* (Diaz-Pifferer). *J Appl Toxicol* 2009; 29(1): 20-6. [http://dx.doi.org/10.1002/jat.1374] [PMID: 18651721]
- [113] Arsianti AA, Fadilah F, Suid K, *et al.* Phytochemical composition and anticancer activity of seaweeds *Ulva lactuca* and *Eucheuma cottonii* against breast MCF-7 and colon HCT-116 cells. *Asian J Pharm Clin Res* 2016; 9(6): 115-9. [http://dx.doi.org/10.22159/ajpcr.2016.v9i6.13798]. [http://dx.doi.org/10.22159/ajpcr.2016.v9i6.13798]
- [114] Catarino MD, Fernandes I, Oliveira H, *et al.* Antitumor Activity of *Fucus vesiculosus*-Derived Phlorotannins through Activation of Apoptotic Signals in Gastric and Colorectal Tumor Cell Lines. *Int J Mol Sci* 2021; 22(14): 7604. [http://dx.doi.org/10.3390/ijms22147604] [PMID: 34299223]
- [115] Omar H, Al-Judaibi A, El-Gendy A. Antimicrobial, Antioxidant, Anticancer Activity and Phytochemical Analysis of the Red Alga, *Laurencia papillosa*. *Int J Pharmacol* 2018; 14(4): 572-83. [https://scialert.net/fulltext/?doi=ijp.2018.572.583]. [http://dx.doi.org/10.3923/ijp.2018.572.583]
- [116] Gross H, Goeger DE, Hills P, *et al.* Lophocladines, bioactive alkaloids from the red alga *Lophocladia* sp. *J Nat Prod* 2006; 69(4): 640-4. [http://dx.doi.org/10.1021/np050519e] [PMID: 16643042]
- [117] Nitecki S, Strain JJ, Magee PI, McSorley EM, Gill CIR. Anticancer Activity of Raw and Digested Irish *Palmaria palmata* Seaweed on *In Vitro* Models of Colorectal Cancer. *Ann Nutr Metab* 2012; 61: 322-36. [https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.673807].
- [118] Vajiravelu S, Subbiah M, Sundaresan B, Natarajan TS. *In vitro* cytotoxic studies of red algae *Portieria hornemannii* and *Spyridia fusiformis* against Dalton's lymphoma ascite and Ehrlich ascite carcinoma cell lines. *J Coast Life Med* 2016; 4(2): 949-52. [https://doi.org/10.12980/jclm.4.2016J6-208].
- [119] Gono CMP, Ahmadi P. A Comprehensive Update on the Bioactive Compounds from Seagrasses Mar. *Drugs* 2022; 20: 97-406. [https://pubmed.ncbi.nlm.nih.gov/35877699/]
- [120] Zhao D, Xie L, Yu L, *et al.* New 2-Benzoxazolinone Derivatives with Cytotoxic Activities from the Roots of *Acanthus ilicifolius*. *Chem Pharm Bull (Tokyo)* 2015; 63(12): 1087-90. [http://dx.doi.org/10.1248/cpb.c15-00597] [PMID: 26633031]
- [121] Babu BH, Shylesh BS, Padikkala J. Tumour reducing and anticarcinogenic activity of *Acanthus ilicifolius* in mice. *J Ethnopharmacol* 2002; 79(1): 27-33. [http://dx.doi.org/10.1016/S0378-8741(01)00347-6] [PMID: 11744292]

- [122] Mitra S, Naskar N, Chaudhuri P. A review on potential bioactive phytochemicals for novel therapeutic applications with special emphasis on mangrove species. *Phytomedicine Plus* 2021; 1(4): 100107. [https://doi.org/10.1016/j.phyplu.2021.100107]. [http://dx.doi.org/10.1016/j.phyplu.2021.100107]
- [123] Firdaus M, Prihanto AA, Nurdiani R. Antioxidant and cytotoxic activity of *Acanthus ilicifolius* flower. *Asian Pac J Trop Biomed* 2013; 3(1): 17-21. [http://dx.doi.org/10.1016/S2221-1691(13)60017-9] [PMID: 23570011]
- [124] Dahibhate NL, Saddhe AA, Kumar K. Mangrove plants as a source of bioactive compounds: a review. *J Nat Prod* 2019; 9(2): 86-97. [https://doi.org/10.2174/2210315508666180910125328].
- [125] Li Y, Dong C, Xu MJ, Lin WH. New alkylated benzoquinones from mangrove plant *Aegiceras corniculatum* with anticancer activity. *J Asian Nat Prod Res* 2020; 22(2): 121-30. [http://dx.doi.org/10.1080/10286020.2018.1540604] [PMID: 30614270]
- [126] Illian DN, Hasibuan PAZ, Sumardi S, Nuryawan A, Wati R, Basyuni M. Anticancer Activity of Polyisoprenoids from *Avicennia alba* Blume. in WiDr Cells. *Iran J Pharm Res* 2019; 18(3): 1477-87. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934958/]. [PMID: 32641956]. [PMID: 32641956]
- [127] Dahibhate NL, Kumar K. Metabolite profiling of *Bruguiera cylindrica* reveals presence of potential bioactive compounds. *PeerJ Analytical Chemistry* 2022; 4: e16. [https://peerj.com/articles/achem-16/]. [http://dx.doi.org/10.7717/peerj-achem.16]
- [128] Chaudhry GS, Tengku Muhammad TS, Rahman NH, *et al.* Induction of cytotoxicity by *Bruguiera gymnorhiza* in human breast carcinoma (MCF-7) cell line *via* activation of the intrinsic pathway. *J Adv Pharm Technol Res* 2020; 11(4): 233-7. [http://dx.doi.org/10.4103/japtr.JAPTR_81_20] [PMID: 33425710]
- [129] Sultana T, Mitra AK, Das S. Evaluation of anti-cancer potential of *Excoecaria agallocha* (L.) leaf extract on human cervical cancer (SiHa) cell line and assessing the underlying mechanism of action. *Future Journal of Pharmaceutical Sciences* 2022; 8(1): 3. [https://fjps.springeropen.com/articles/10.1186/s43094-021-00389-y#]. [http://dx.doi.org/10.1186/s43094-021-00389-y]
- [130] Venkateswarulu TC, Eswaraiah G, Krupanidhi S, *et al.* Screening of *Ipomoea tuba* Leaf Extract for Identification of Bioactive Constituents and Evaluation of Its *in vitro* Anti-Proliferative Activity Against MCF-7 and HeLa Cells. *Food Technol Biotechnol* 2020; 58(1): 71-85. [http://dx.doi.org/10.17113/ftb.58.01.20.6351] [PMID: 32684790]
- [131] Prabhu VV, Guruvayoorappan C. Anti-inflammatory and anti-tumor activity of the marine mangrove *Rhizophora apiculata*. *J Immunotoxicol* 2012; 9(4): 341-52. [http://dx.doi.org/10.3109/1547691X.2012.660997] [PMID: 22800297]
- [132] Gong KK, Li PL, Qiao D, *et al.* Cytotoxic and Antiviral Triterpenoids from the Mangrove Plant *Sonneratia paracaseolaris*. *Molecules* 2017; 22(8): 1319. [http://dx.doi.org/10.3390/molecules22081319] [PMID: 28792469]
- [133] Darmadi J, Batubara RR, Himawan S, *et al.* Evaluation of Indonesian mangrove *Xylocarpus granatum* leaves ethyl acetate extract as potential anticancer drug. *Sci Rep* 2021; 11(1): 6080. [https://www.nature.com/articles/s41598-021-85383-3] [http://dx.doi.org/10.1038/s41598-021-85383-3] [PMID: 33727582]
- [134] Jing L, Feng L, Zhou Z, *et al.* Limonoid compounds from *Xylocarpus granatum* and their anticancer activity against esophageal cancer cells. *Thorac Cancer* 2020; 11(7): 1817-26. [http://dx.doi.org/10.1111/1759-7714.13455] [PMID: 32449599]
- [135] Karan S, Turan C, Sangun MK, Eliuz EAE. Bioactive Compounds and Antimicrobial Activity of Glasswort *Salicornia europaea* *Indian J Pharm Sci* 2021; 83(2): 229-37. [https://www.ijpsonline.com/articles/].

- [136] Altay A, Celep GS, Yaprak AE, Baskose I, Bozoglu F. Glassworts as Possible Anticancer Agents Against Human Colorectal Adenocarcinoma Cells with Their Nutritive, Antioxidant and Phytochemical Profiles. *Chem Biodivers* 2017; 14(3): e1600290. [http://dx.doi.org/10.1002/cbdv.201600290]
- [137] Wu CF, Lee MG, El-Shazly M, *et al.* Isoaaptamine Induces T-47D Cells Apoptosis and Autophagy via Oxidative Stress. *Mar Drugs* 2018; 16(1): 18. [http://dx.doi.org/10.3390/md16010018] [PMID: 29315210]
- [138] Yu H. + 8. Cytotoxic Aaptamine Derivatives from the South China Sea Sponge *Aaptos aaptos* *J Nat Prod* 2014; 77(9): 2124-9. [http://dx.doi.org/10.1021/np500583z]
- [139] Liu C, Tang X, Li P, Li G, Suberitine A-D. Suberitine A-D, four new cytotoxic dimeric aaptamine alkaloids from the marine sponge *Aaptos suberitoides*. *Org Lett* 2012; 14(8): 1994-7. [http://dx.doi.org/10.1021/ol3004589] [PMID: 22472093]
- [140] Murniasih T, Putra MY, Bau A, Wibowo JT. A Review on Diversity of Anticancer Compounds Derived from Indonesian Marine Sponges. *IOP Conf Ser: Mater Sci Eng.* [https://iopscience.iop.org/article/10.1088/1757-899X/1192/1/012012/meta]
- [141] Wilke DV. + 7. Anticancer Potential of Compounds from the Brazilian Blue Amazon. *Planta Med* 2021; 87(1-02): 49-70. https://pubmed.ncbi.nlm.nih.gov/33142347/
- [142] Shakeel S, Dykeman EC, White SJ, *et al.* Genomic RNA folding mediates assembly of human parechovirus. *Nat Commun* 2017; 8(1): 5. [http://dx.doi.org/10.1038/s41467-016-0011-z] [PMID: 28232749]
- [143] van Kesteren C, de Vooght MMM, López-Lázaro L, *et al.* Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin. *Anticancer Drugs* 2003; 14(7): 487-502. [http://dx.doi.org/10.1097/00001813-200308000-00001] [PMID: 12960733]
- [144] Anjum K, Abbas SQ, Shah SAA, Akhter N, Batool S, Hassan SS. Marine Sponges as a Drug Treasure. *Biomol Ther (Seoul)* 2016; 24(4): 347-62. [http://dx.doi.org/10.4062/biomolther.2016.067] [PMID: 27350338]
- [145] Kijjoa A, Wattanadilok R, Herz W, Campos N, Nascimento M, Pinto M. Anticancer activity evaluation of kuanoniamines A and C isolated from the marine sponge *Oceanapia sagittaria*, collected from the Gulf of Thailand. *Mar Drugs* 2007; 5(2): 6-22. [http://dx.doi.org/10.3390/md502006] [PMID: 18463725]
- [146] Warabi K, Matsunaga S, van Soest RWM, Fusetani N. Dictyodendrins A-E, the first telomerase-inhibitory marine natural products from the sponge *Dictyodendrilla verongiformis*. *J Org Chem* 2003; 68(7): 2765-70. https://pubmed.ncbi.nlm.nih.gov/12662050/
- [147] Tasdemir D, Mallon R, Greenstein M, *et al.* Aldisine alkaloids from the Philippine sponge *Stylissa massa* are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). *J Med Chem* 2002; 45(2): 529-32. [http://dx.doi.org/10.1021/jm0102856] [PMID: 11784156]
- [148] Halim H, Chunchacha P, Suwanborirux K, Chanvorachote P. Anticancer and antimetastatic activities of Renieramycin M, a marine tetrahydroisoquinoline alkaloid, in human non-small cell lung cancer cells. *Anticancer Res* 2011; 31(1): 193-201. [https://pubmed.ncbi.nlm.nih.gov/21273598/]. [PMID: 21273598]. [PMID: 21273598]
- [149] Tang WZ, Lu JR, Wang GF, *et al.* New norterpene cyclic peroxides and a new polyketide from the marine sponge *Diacarnus megaspinorhabdosa*. *Tetrahedron Lett* 2021; 74(22): 153155. [https://doi.org/10.1016/j.tetlet.2021.153155]. [http://dx.doi.org/10.1016/j.tetlet.2021.153155]
- [150] Alarif WM, Al-Lihaibi SS, Ghandourah MA, Orif MI, Basaif SA, Ayyad SEN. Cytotoxic scalarane-

- type sesterterpenes from the Saudi Red Sea sponge *Hyrtios erectus*. J Asian Nat Prod Res 2016; 18(6): 611-7.
[<http://dx.doi.org/10.1080/10286020.2015.1115019>] [PMID: 26630474]
- [151] Ahn JH, Woo JH, Rho JR, Choi JH. Anticancer Activity of Gukulenin A Isolated from the Marine Sponge *Phorbos gukhulensis* *In Vitro* and *In Vivo*. Mar Drugs 2019; 17(2): 126.
[<http://dx.doi.org/10.3390/md17020126>] [PMID: 30795557]
- [152] Kuznetsov G, TenDyke K, Towle MJ, *et al.* Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiamsterlin. Mol Cancer Ther 2009; 8(10): 2852-60.
[<http://dx.doi.org/10.1158/1535-7163.MCT-09-0301>] [PMID: 19825803]
- [153] Arai M, Yamano Y, Fujita M, Setiawan A, Kobayashi M. Stylistamide X, a new proline-rich cyclic octapeptide as an inhibitor of cell migration, from an Indonesian marine sponge of *Stylissa* sp. Bioorg Med Chem Lett 2012; 22(4): 1818-21.
[<http://dx.doi.org/10.1016/j.bmcl.2011.10.023>] [PMID: 22260773]
- [154] Hasin O, Shoham S, Kashman Y, Ilan M, Carmeli S. Theonellamides J and K and 5- *cis*-Apoa-theopalauamide, Bicyclic Glycopeptides of the Red Sea Sponge *Theonella swinhoei*. Mar Drugs 2021; 20(1): 31.
[<http://dx.doi.org/10.3390/md20010031>] [PMID: 35049886]
- [155] Govindam SVS, Choi BK, Yoshioka Y, *et al.* Novel cytotoxic polyoxygenated steroids from an Okinawan sponge *Dysidea* sp. Biosci Biotechnol Biochem 2012; 76(5): 999-1002.
[<http://dx.doi.org/10.1271/bbb.120017>] [PMID: 22738973]
- [156] Li J, Wang Z, Yang F, Jiao WH, Lin HW, Xu SH. Two new steroids with cytotoxicity from the marine sponge *Dactylopongia elegans* collected from the South China Sea. Nat Prod Res 2019; 33(9): 1340-4.
[<http://dx.doi.org/10.1080/14786419.2018.1475385>] [PMID: 29863897]
- [157] Trinh TTV. + 7. New 9 α -Hydroxy-5 α ,6 α -epoxyhydroxysterols from the Vietnamese Marine Sponge *Ircinia echinata*. Mar Drugs 2018; 16(11): 424.
[<http://dx.doi.org/10.3390/md16110424>] [PMID: 30388820]
- [158] Mun B. + 13. Cytotoxic 5 α ,8 α -epidioxy sterols from the marine sponge *Monanchora* sp. Arch Pharm Res 2015; 38(1): 18-25.
[<http://dx.doi.org/10.1007/s12272-014-0480-8>] [PMID: 25231340]
- [159] Pailee P, Mahidol C, Ruchirawat S, Prachywarakorn V. Sterols from Thai Marine Sponge *Petrosia (Strongylophora)* sp. and Their Cytotoxicity. Mar Drugs 2017; 15(3): 54.
[<http://dx.doi.org/10.3390/md15030054>] [PMID: 28241489]
- [160] Li J, Tang H, Kurtán T, *et al.* Swinhoeisterols from the South China Sea Sponge *Theonella swinhoei*. J Nat Prod 2018; 81(7): 1645-50.
[<http://dx.doi.org/10.1021/acs.jnatprod.8b00281>] [PMID: 29989811]
- [161] Rodríguez J, Jiménez C, Blanco M, Tarazona G, Fernández R, Cuevas C. Lanesoic Acid: A Cytotoxic Zwitterion from *Theonella* sp. Org Lett 2016; 18(22): 5832-5.
[<http://dx.doi.org/10.1021/acs.orglett.6b02832>] [PMID: 27802052]
- [162] Lai KH, Peng BR, Su CH, *et al.* Anti-Proliferative Potential of Secondary Metabolites from the Marine Sponge *Theonella* sp.: Moving from Correlation toward Causation. Metabolites 2021; 11(8): 532.
[<http://dx.doi.org/10.3390/metabo11080532>] [PMID: 34436473]
- [163] Chen M, Wu XD, Zhao Q, Wang CY. Topsissterols A–C, Cytotoxic Polyhydroxylated Sterol Derivatives from a Marine Sponge *Topsentia* sp. Mar Drugs 2016; 14(8): 146.
[<http://dx.doi.org/10.3390/md14080146>] [PMID: 27490555]
- [164] El-Gamal A, Al-Massarani S, Shaala L, *et al.* Cytotoxic Compounds from the Saudi Red Sea Sponge *Xestospongia testudinaria*. Mar Drugs 2016; 14(5): 82.

- [http://dx.doi.org/10.3390/md14050082] [PMID: 27128926]
- [165] Iguchi K, Shimura H, Taira S, Yokoo C, Matsumoto K, Yamada Y. Aragusterol B and D, new 26,27-cyclosterols from the Okinawan marine sponge of the genus *Xestospongia*. *J Org Chem* 1994; 59(24): 7499-502. [https://doi.org/10.1021/jo00103a053]. [http://dx.doi.org/10.1021/jo00103a053]
- [166] Chantarawong W, Chamni S, Suwanborirux K, Saito N, Chanvorachote P. 5-O-Acetyl-Renieramycin T from Blue Sponge drug sources: chemical and biological aspects. *Acta Pharm Sin B* 2019; 9(2): 237-57. [http://dx.doi.org/10.1016/j.apsb.2018.10.003] [PMID: 30972275]
- [167] Ortega V, Cortés J. Potential clinical applications of halichondrins in breast cancer and other neoplasms. *Breast Cancer (Dove Med Press)* 2012; 4: 9-19. [https://pubmed.ncbi.nlm.nih.gov/24367189/]. [PMID: 24367189]. [PMID: 24367189]
- [168] McBride A, Butler SK. Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer. *Am J Health Syst Pharm* 2012; 69(9): 745-55. [http://dx.doi.org/10.2146/ajhp110237] [PMID: 22517020]
- [169] Roll DM, Scheuer PJ, Matsumoto GK, Clardy J. Halenaquinone, a pentacyclic polyketide from a marine sponge. *J Am Chem Soc* 1983; 105(19): 6177-8. [https://doi.org/10.1021/ja00357a049]. [http://dx.doi.org/10.1021/ja00357a049]
- [170] Jimenez PC, Wilke DV, Costa-Lotufo LV. Marine drugs for cancer: surfacing biotechnological innovations from the oceans. *Clinics (São Paulo)* 2018; 73 (Suppl. 1): e482s. [http://dx.doi.org/10.6061/clinics/2018/e482s] [PMID: 30133563]
- [171] Schwartzmann G, da Rocha AB, Berlinck RGS, Jimeno J, Oncol L. Marine organisms as a source of new anticancer agents. *Lancet Oncol* 2001; 2(4): 221-5. [http://dx.doi.org/10.1016/S1470-2045(00)00292-8] [PMID: 11905767]
- [172] Hunt ME, Modi CK, Aglyamova GV, Ravikant DVS, Meyer E, Matz MV. Multi-domain GFP-like proteins from two species of marine hydrozoans. *Photochem Photobiol Sci* 2012; 11(4): 637-44. [http://dx.doi.org/10.1039/c1pp05238a] [PMID: 22251928]
- [173] Kawabata T, Lindsay DJ, Kitamura M, et al. Evaluation of the bioactivities of water-soluble extracts from twelve deep-sea jellyfish species. *Fish Sci* 2013; 79(3): 487-94. [https://doi.org/10.1007/s12562-013-0612-y]. [http://dx.doi.org/10.1007/s12562-013-0612-y]
- [174] Mariottini G, Pane L. Cytotoxic and cytolytic cnidarian venoms. A review on health implications and possible therapeutic applications. *Toxins (Basel)* 2013; 6(1): 108-51. [http://dx.doi.org/10.3390/toxins6010108] [PMID: 24379089]
- [175] Korsmo KA. Isolation and characterization of bioactive compounds from the marine hydrozoans *Halecium muricatum* and *Halecium beanie*. 2012. [https://munin.uit.no/bitstream/handle/10037/4327/thesis.pdf?sequence=2]
- [176] Sala S, Micke SK, Flematti GR. Marine Natural Products from Flora and Fauna of the Western Australian Coast: Taxonomy, Isolation and Biological Activity. *Molecules* 2023; 28(3): 1452. [http://dx.doi.org/10.3390/molecules28031452] [PMID: 36771114]
- [177] Kang C, Munawir A, Cha M, et al. Cytotoxicity and hemolytic activity of jellyfish *Nemopilema nomurai* (Scyphozoa: Rhizostomeae) venom. *Comp Biochem Physiol C Toxicol Pharmacol* 2009; 150(1): 85-90. [http://dx.doi.org/10.1016/j.cbpc.2009.03.003] [PMID: 19303056]
- [178] Su YD, Su JH, Hwang TL, et al. Briarane Diterpenoids Isolated from Octocorals between 2014 and 2016. *Mar Drugs* 2017; 15(2): 44. [http://dx.doi.org/10.3390/md15020044] [PMID: 28218675]

- [179] Xio YJ, Su JH, Chen BW, Tseng YJ, Wu YC, Sheu JH. Oxygenated ylangene-derived sesquiterpenoids from the soft coral *Lemnalia philippinensis*. *Mar Drugs* 2013; 11(10): 3735-41. [<http://dx.doi.org/10.3390/md11103735>] [PMID: 24084789]
- [180] Moritz M, Marostica L, Bianco É, *et al.* Polyoxygenated steroids from the octocoral *Leptogorgia punicea* and *in vitro* evaluation of their cytotoxic activity. *Mar Drugs* 2014; 12(12): 5864-80. [<http://dx.doi.org/10.3390/md12125864>] [PMID: 25486111]
- [181] Ng SY, Phan CS, Ishii T, Kamada T, Hamada T, Vairappan CS. Terpenoids from Marine Soft Coral of the Genus *Xenia* in 1977 to 2019. *Molecules* 2020; 25(22): 5386. [<http://dx.doi.org/10.3390/molecules25225386>] [PMID: 33217924]
- [182] Ciavatta ML, Lefranc F, Carbone M, *et al.* Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. *Med Res Rev* 2017; 37(4): 702-801. [<http://dx.doi.org/10.1002/med.21423>] [PMID: 27925266]
- [183] Santhanam R, Ramesh S, David SR. *Biology and Ecology of Pharmaceutical Marine Life: Echinoderms (Series: Biology and Ecology of Pharmaceutical Marine Life)* CRC Press. USA: Taylor & Francis 2019. c[<https://www.taylorfrancis.com/books/mono/10.1201/9780429060236/>] [<http://dx.doi.org/10.1201/9780429060236>]
- [184] Azad N, Najdegerami EH, Imani M, Nikoo M. Bioactive peptides from the Pacific white-leg shrimp (*Litopenaeus vannamei*) induce apoptosis and anticancer activities in HCT-116 colon cancer cell line. *Iran J Fish Sci* 2022; 21(5): 1180-91. [http://jifro.ir/browse.php?a_code=A-10-25-9-2&slc_lang=en&sid=1].
- [185] Behera A, Das R, Patnaik P, Mohanty J, Mohanty G. A review on fish peptides isolated from fish waste with their potent bioactivities. *J Appl Biol Biotechnol* 2022; 10(03): 195-209. [<http://dx.doi.org/10.7324/JABB.2022.100323>]
- [186] Kannan A, Hettiarachchy NS, Marshall M, Raghavan S, Kristinsson H. Shrimp shell peptide hydrolysates inhibit human cancer cell proliferation. *J Sci Food Agric* 2011; 15;91(10): 1920-4.
- [187] Priya ER, Ravichandr S. Anti Cancer Compounds of *Calappa calappa* L. (1758). *International Journal of Zoological Research* 2015; 11(3): 107-11. [<https://scialert.net/fulltext/?doi=ijzr.2015.107.111>]. [<http://dx.doi.org/10.3923/ijzr.2015.107.111>]
- [188] Doyen A, Beaulieu L, Saucier L, Pouliot Y, Bazinet L. Demonstration of *in vitro* anticancer properties of peptide fractions from a snow crab by-products hydrolysate after separation by electrodialysis with ultrafiltration membranes. *Separ Purif Tech* 2011; 78(3): 321-9. [<https://doi.org/10.1016/j.seppur.2011.01.037>]. [<http://dx.doi.org/10.1016/j.seppur.2011.01.037>]
- [189] Kavitha R, Aiswarya s, Ratnavali CMG. Anticancer activity of red pigment from *Serratia marcescens* in Human cervix carcinoma. *Int J Pharm Tech Res* 2010; 2(1): 784-7. [[https://sphinxesai.com/sphinxesai_vol_2no.1/pharmtech_vol_2no.1/PharmTech_Vol_2No.1PDF/PT=120%20\(784-787\).pdf](https://sphinxesai.com/sphinxesai_vol_2no.1/pharmtech_vol_2no.1/PharmTech_Vol_2No.1PDF/PT=120%20(784-787).pdf)].
- [190] Baharlouei P, Rahman A. Chitin and Chitosan. *Mar Drugs* 2022; 20(7): 460. [<http://dx.doi.org/10.3390/md20070460>] [PMID: 35877753]
- [191] Hadrian E, Sari AP, Mayanti T, *et al.* Steroids from *Atactodea striata* and Their Cytotoxic Activity against MCF-7 Breast Cancer Cell Lines. *Indonesian Journal of Chemistry* 2022; 23(1): 200-9. [<https://doi.org/10.22146/ijc.76438>]. [<http://dx.doi.org/10.22146/ijc.76438>]
- [192] Odeleye T, White W, Lu J. Cytotoxicity of Extracts from New Zealand Surf Clams Against Organ Cancer Cell Lines. *Biomedicines* 2019; 7(2): 25. [<http://dx.doi.org/10.3390/biomedicines7020025>] [PMID: 30935008]
- [193] Cheong SH, Kim EK, Hwang JW, *et al.* Purification of a novel peptide derived from a shellfish,

- Crassostrea gigas*, and evaluation of its anticancer property. *J Agric Food Chem* 2013; 61(47): 11442-6.
[<http://dx.doi.org/10.1021/jf4032553>] [PMID: 24199654]
- [194] Honari M, Tehranifard A, Vazirian M, Salaritabar A, Sanati H, Ansari AM. Cytotoxic Effect of *Turbo coronatus* Extract on Cancer Cell Lines. *RRJPPS* 2017; 6(1): 55-8. [<https://doi.org/10.3390/antiox12020386>].
- [195] Tortorella E, Giugliano R, De Troch M, Vlaeminck B, de Viçose GC, de Pascale D. The Ethyl Acetate Extract of the Marine Edible Gastropod *Haliotis tuberculata* coccinea: a Potential Source of Bioactive Compounds. *Mar Biotechnol (NY)* 2021; 23(6): 892-903.
[<http://dx.doi.org/10.1007/s10126-021-10073-0>] [PMID: 34714443]
- [196] Jeyasanta I, Patterson J. Bioactive Properties of Ink Gland Extract from Squid *Loligo duvauceli*. *Ecología (Madr)* 2019; 10(1): 9-19. [<https://scialert.net/abstract/?doi=ecologia.2020.9.19>].
[<http://dx.doi.org/10.3923/ecologia.2020.9.19>]
- [197] Hernández-Zazueta MS, Luzardo-Ocampo I, García-Romo JS, *et al.* Bioactive compounds from *Octopus vulgaris* ink extracts exerted anti-proliferative and anti-inflammatory effects *in vitro*. *Food Chem Toxicol* 2021; 151: 112119.
[<http://dx.doi.org/10.1016/j.fct.2021.112119>] [PMID: 33722603]
- [198] Lazzara V, Arizza V, Luparello C, Mauro M, Vazzana M. Bright Spots in The Darkness of Cancer: A Review of Starfishes-Derived Compounds and Their Anti-Tumor Action. *Mar Drugs* 2019; 17(11): 617.
[<http://dx.doi.org/10.3390/md17110617>] [PMID: 31671922]
- [199] Baharara J, Amini E. The Potential of Brittle Star Extracted Polysaccharide in Promoting Apoptosis via Intrinsic Signaling Pathway. *Avicenna J Med Biotechnol* 2015; 7(4): 151-8.
[PMID: 26605009]
- [200] Klimenko A, Rodina EE, Silachev D, *et al.* Chlorin Endogenous to the North Pacific Brittle Star *Ophiura sarsii* for Photodynamic Therapy Applications in Breast Cancer and Glioblastoma Models. *Biomedicines* 2022; 10(1): 134.
[<http://dx.doi.org/10.3390/biomedicines10010134>] [PMID: 35052813]
- [201] Thao NP, Luyen BTT, Kim EJ, *et al.* Steroidal constituents from the edible sea urchin *Diadema savignyi* Michelin induce apoptosis in human cancer cells. *J Med Food* 2015; 18(1): 45-53.
[<http://dx.doi.org/10.1089/jmf.2013.3105>] [PMID: 25211186]
- [202] Brasseur L, Hennebert E, Fievez L, *et al.* The Roles of Spinochromes in Four Shallow Water Tropical Sea Urchins and Their Potential as Bioactive Pharmacological Agents. *Mar Drugs* 2017; 15(6): 179.
[<http://dx.doi.org/10.3390/md15060179>] [PMID: 28621734]
- [203] Mishchenko NP, Vasileva EA, Gerasimenko AV, Grigorichuk VP, Dmitrenok PS, Fedoreyev SA. Isolation and Structure Determination of Echinochrome A Oxidative Degradation Products. *Molecules* 2020; 25(20): 4778.
[<http://dx.doi.org/10.3390/molecules25204778>] [PMID: 33080948]
- [204] Russo G, Russo M, Castellano I, Napolitano A, Palumbo A. Ovothiol isolated from sea urchin oocytes induces autophagy in the Hep-G2 cell line. *Mar Drugs* 2014; 12(7): 4069-85.
[<http://dx.doi.org/10.3390/md12074069>] [PMID: 25003791]
- [205] Sahara H, Ishikawa M, Takahashi N, *et al.* *In vivo* anti-tumour effect of 3'-sulphonoquinovosyl 1'-monoacylglyceride isolated from sea urchin (*Strongylocentrotus intermedius*) intestine. *Br J Cancer* 1997; 75(3): 324-32.
[<http://dx.doi.org/10.1038/bjc.1997.54>] [PMID: 9020475]
- [206] Wang H, Wang M, Chen J, *et al.* A polysaccharide from *Strongylocentrotus nudus* eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. *Int Immunopharmacol* 2011; 11(11): 1946-53.
[<http://dx.doi.org/10.1016/j.intimp.2011.06.006>] [PMID: 21723424]

- [207] Wu L, Yang X, Duan X, Cui L, Li G. Exogenous expression of marine lectins DIFBL and SpRBL induces cancer cell apoptosis possibly through PRMT5-E2F-1 pathway. *Sci Rep* 2014; 4(1): 4505. [http://dx.doi.org/10.1038/srep04505] [PMID: 24675921]
- [208] Hou Y, Vasileva EA, Carne A, McConnell M, El-Din A Bekhit A, Mishchenko NP. Naphthoquinones of the spinochrome class: occurrence, isolation, biosynthesis and biomedical applications. *RSC Advances* 2018; 8(57): 32637-50. [http://dx.doi.org/10.1039/C8RA04777D] [PMID: 35547692]
- [209] Wätjen W, Ebada SS, Bergermann A, *et al.* Cytotoxic effects of the anthraquinone derivatives 1'-deoxyrhodoptilometrin and (S)-(-)-rhodoptilometrin isolated from the marine echinoderm *Comanthus* sp. *Arch Toxicol* 2017; 91(3): 1485-95. [http://dx.doi.org/10.1007/s00204-016-1787-7] [PMID: 27473261]
- [210] Nagle DG, Zhou YD. Marine natural products as inhibitors of hypoxic signaling in tumors. *Phytochem Rev* 2009; 8(2): 415-29. [http://dx.doi.org/10.1007/s11101-009-9120-1] [PMID: 20622986]
- [211] Ebada S, Wray V, Edrada R, Proksch P. Anthraquinones and naphthopyrones from the marine echinoderm *Comanthus* sp. *Planta Med* 2009; 75(9): 75-PE11. [https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0029-1234572]. [http://dx.doi.org/10.1055/s-0029-1234572]
- [212] Khokhar S, Pierens GK, Hooper JNA, Ekins MG, Feng Y, Davis RA. Rhodocomatulin-Type Anthraquinones from the Australian Marine Invertebrates *Clathria hirsuta* and *Comatula rotularia*. *J Nat Prod* 2016; 79(4): 946-53. [http://dx.doi.org/10.1021/acs.jnatprod.5b01029] [PMID: 27063022]
- [213] Yun SH, Sim EH, Han SH, *et al.* Holotoxin A1 Induces Apoptosis by Activating Acid Sphingomyelinase and Neutral Sphingomyelinase in K562 and Human Primary Leukemia Cells. *Mar Drugs* 2018; 16(4): 123. [http://dx.doi.org/10.3390/md16040123] [PMID: 29642569]
- [214] Janakiram N, Mohammed A, Rao C. Sea Cucumbers Metabolites as Potent Anti-Cancer Agents. *Mar Drugs* 2015; 13(5): 2909-23. [http://dx.doi.org/10.3390/md13052909] [PMID: 25984989]
- [215] Mashjoor S, Yousefzad M, Pishavarzad F. Assessment of anticancer potential of selected *Holothuria* species. *Indian J Tradit Knowl* 2019; 18(2): 272-80. [https://core.ac.uk/download/pdf/297999269.pdf].
- [216] Zhang JJ, Zhu KQ. A novel antitumor compound nobiliside D isolated from sea cucumber (*Holothuria nobilis* Selenka). *Exp Ther Med* 2017; 14(2): 1653-8. [http://dx.doi.org/10.3892/etm.2017.4656] [PMID: 28810632]
- [217] Zou ZR, Yi YH, Wu HM, Wu JH, Liaw CC, Lee KH. Intercedensides A-C, three new cytotoxic triterpene glycosides from the sea cucumber *Mensamaria intercedens* Lampert. *J Nat Prod* 2003; 66(8): 1055-60. [http://dx.doi.org/10.1021/np030064y] [PMID: 12932123]
- [218] Zou Z, Yi Y, Wu H, *et al.* Intercedensides D-I, cytotoxic triterpene glycosides from the sea cucumber *Mensamaria intercedens* Lampert. *J Nat Prod* 2005; 68(4): 540-6. [http://dx.doi.org/10.1021/np040205b] [PMID: 15844944]
- [219] Wargasetia TL, Ratnawati H, Widodo N. Sea Cucumber Compounds Targeting NF-κB in Cancer Treatment. *Bioinform Biol Insights* 2022; 16 [http://dx.doi.org/10.1177/11779322221091740] [PMID: 35462875]
- [220] Santhanam R, Ramesh S, Nivedhitha S, Balasundari S. *Pharmaceuticals and Nutraceuticals from Fish and Fish Wastes*. USA: Apple Academic Press 2022. [https://www.appleacademicpress.com/pharmaceuticals-and-nutraceuticals-from-fish-and-fish-wastes-/9781774630105]

- [http://dx.doi.org/10.1201/9781003180548]
- [221] Palanisamy SK, Rajendran NM, Marino A. Natural Products Diversity of Marine Ascidiaceans (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development. *Nat Prod Bioprospect* 2017; 7(1): 1-111. [http://dx.doi.org/10.1007/s13659-016-0115-5] [PMID: 28097641]
- [222] Vervoort H, Fenical W, Epifanio RA. Tamandarins A and B: new cytotoxic depsipeptides from a Brazilian ascidian of the family Didemnidae. *J Org Chem* 2000; 65(3): 782-92. [http://dx.doi.org/10.1021/jo991425a] [PMID: 10814011]
- [223] Badre A, Boulanger A, Abou-Mansour E, Banaigs B, Combaut G, Francisco C. Eudistomin U and isoeudistomin U, new alkaloids from the Caribbean ascidian *Lissoclinum fragile*. *J Nat Prod* 1994; 57(4): 528-33. [http://dx.doi.org/10.1021/np50106a016] [PMID: 8021654]
- [224] Nurdiani R, Vasiljevic T, Singh TK, Donkor ON. ON. Bioactive peptides from fish by-products with anticarcinogenic potential. *Int Food Res J* 2017; 4(5): 1840-9. <https://www.cabdirect.org/cabdirect/abstract/20183067238>
- [225] Pangestuti R, Kim SK. Bioactive Peptide of Marine Origin for the Prevention and Treatment of Non-Communicable Diseases. *Mar Drugs* 2017; 15(3): 67. [http://dx.doi.org/10.3390/md15030067] [PMID: 28282929]
- [226] <https://clinicaltrials.gov/ct2/show/NCT0000599>
- [227] Varier KM, Chinnasamy A, Gajendran B, Nagarathnam R. Isolation and characterization of a novel anticancer muscle protein from edible marine catfish *Tachysurus dussumieri*. *Int J Pharm Sci Res* 2018; 9: 2720-30. [http://dx.doi.org/10.13040/IJPSR.0975-8232.9(7).2720-30].
- [228] Oda T, Fujiwara T, Liu H, *et al.* Effects of Lissoclibadins and Lissoclinotoxins, Isolated from a Tropical Ascidian *Lissoclinum cf. badium*, on IL-8 production in a PMA-stimulated Promyelocytic Leukemia Cell Line. *Mar Drugs* 2006; 4(1): 15-21. [http://dx.doi.org/10.3390/md401015]

SUBJECT INDEX

A

- Acid 16, 82, 102, 103, 105, 150, 194, 195, 214, 215, 262, 329, 330, 331, 336
 benzoic 105
 betulinic 102, 103
 brominated phenylacetic 331
 chlorosulfonic 262
 docosahexaenoic 82
 gallic 16
 hexadecanoic 262
 Isishippuric 214
 paraminabic 194, 195, 215
 stoloniac 329, 330, 336
- Actinomycetes 13, 32
- Activity 4, 5, 11, 16, 23, 26, 27, 47, 48, 49, 63, 73, 74, 76, 89, 94, 95, 113, 118, 131, 135, 151, 176, 203, 294, 338
 antagonistic 11
 anti-inflammatory 16, 113
 antifungal 76
 antileukemic 89
 antimetastatic 151
 antiproliferative 131
 catalase 176
 enzyme 118
 metastatic 338
 tumor-inhibiting 23
- Acute 33, 35, 309
 inflammatory responses 309
 myeloid leukemia 33, 35
- Adenocarcinoma, stomach 211
- Angiogenesis process 338
- Anthenoside 263, 264
- Anthraquinone compounds 285
- Anti angiogenic effects 337, 338
- Anti cancer 1, 46, 48, 217
 activities 46, 48
 compounds 1, 217
- Anti hypertensive 232
- Anti-inflammatory agents 232
- Anti metastatic effects 262
- Anti microtubule agents 9
- Anti-proliferative 16, 17, 263, 283, 287, 294, 316, 325
 activity 16, 263, 283, 316, 325
 effects 17, 287, 294
- Anti-tumor activity 109, 197
- Anti-tumor effects 16, 46, 70, 99, 105, 240, 243, 261
 displayed promising 70
 exhibited 99, 105, 240, 243
 promising 99
- Anti-tumoral effects 98
- Antibiotics 4, 15, 17, 33, 337
 anti-tumor 17
- Antibody-drug conjugates (ADC) 18, 21, 22, 23, 26, 27, 32, 33, 34, 35, 36
- Antibreast cancer agents 98
- Anticancer 1, 3, 7, 8, 9, 10, 13, 16, 17, 18, 20, 21, 22, 41, 43, 44, 45, 71, 72, 74, 75, 84, 85, 92, 93, 95, 96, 107, 109, 112, 113, 127, 159, 160, 172, 208, 217, 218, 231, 275, 281, 292, 295, 335, 336
 agents 9, 18, 113
 antibiotics 17
 compounds of marine stony 208
 drugs 1, 7, 17, 21, 22, 45, 113, 218
 effects 16, 71, 72, 74, 75, 84, 85, 92, 93, 95, 96
 function 20, 41, 43
 metabolites 44, 231, 275, 281, 295
 organic 159, 160
 therapies 127, 292
- Anticancer marine 1, 8
 biodiversity 8
 compounds 1
 plants 8
- Anticorectal cancer agents 98
- Antimicrobial properties 12, 232
- Antimitotic 97, 159, 262
 activity 159
 effects 97, 262

- Antiproliferative 16, 47, 59, 67, 84, 89, 92, 93, 261, 337, 338, 339, 340
activity 16, 47, 59, 67, 84, 89, 261, 337, 338, 339, 340
effects 92, 93, 339
- Anti-tumor 9, 13, 48, 105, 117
activity 9, 48, 105, 117
agents 13
- Anti-tumor effects 134, 283
displayed 134
- Apoptosis 3, 70, 92, 99, 102, 103, 113, 114, 115, 118, 119, 151, 176, 177, 262, 273, 276, 287
activating 92
cisplatin-mediated 151
induction 276
- Apoptotic 4, 90, 92, 101, 133, 199, 227, 241, 262, 290
activity 90, 101, 133, 199, 227, 241, 262
displayed 92
- B**
- Bladder cancers 22
- Breast cancer 21, 26, 91, 94, 145, 170, 175, 189, 197, 234, 262, 267, 271, 274
metastatic 21, 26
metastasis 145
- Breast carcinoma 72, 173, 197, 203, 226, 237, 317, 320
- C**
- Cancer 1, 2, 3, 4, 20, 27, 33, 34, 35, 46, 48, 75, 85, 166, 172, 189, 217, 221, 236, 239, 240, 247, 248, 256, 299, 310, 338
blood 4, 221
chemotherapy 256
colorectal 33, 239, 310
esophageal 217, 247
gastric 27
kidney 75, 299
managing 33
metastasis 256
migration 48
oesophageal 34
oral 248, 338
renal 189, 236
uterus 2
- Cancer cells 9, 75, 84, 96, 99, 103, 135, 150, 151, 153, 154, 156, 158, 162, 164, 165, 173, 175, 216, 232, 233, 235, 237, 239, 338
kidney 75, 338
liver 103, 232
lung 75, 84, 151, 164, 235
malignant 216
oral 338
ovarian 75, 135
- Carcinogenesis 3
- Carcinogenetic process 171
- Carcinoma 27, 99, 100, 200, 230, 241, 243, 249, 256, 258, 266, 286
breast cell 286
cervix 243, 249, 256, 258
esophageal 266
metastatic 100
renal 230
squamous cell 200, 241
- Cardiovascular diseases 46
- Cell transformation, inhibiting 274
- Cellular DNA damage 96
- Cervical 92, 150, 190, 326
cancer 150, 190, 326
carcinoma 92
- Cervix 211, 252, 256, 259
cancer 252, 256, 259
carcinoma cells 211
- Chemicals 2, 6, 15
anti cancer 6
- Chemotherapy 3, 12, 23, 217
medication 217
platinum-based 23
- Colon 2, 47, 63, 64, 67, 72, 73, 74, 93, 102, 176, 177, 178, 187, 190, 201, 208, 209, 239, 243, 244, 247, 266, 285, 307, 308
adenocarcinoma 63, 72, 73, 93, 190, 201, 208, 266, 307, 308
cancer 2, 67, 74, 176, 177, 187, 209, 239, 243, 244, 247
carcinoma 47, 64, 102, 178, 285
- Colorectal 67, 75, 91, 99, 185, 233, 240, 247, 300, 331
adenocarcinoma 99, 185, 233
cancer stem cells 99
carcinoma 67, 75, 91, 240, 247, 300, 331
- Cyclic 277, 336
peroxides *Stolonica* 336
steroid glycosides 277

Subject Index

Cyclin-dependent kinase (CDK) 118, 266
Cyclodepsipeptide 62
Cytokinesis, inhibited 84
Cytostatic 284
 efforts 284
Cytotoxic 13, 17, 23, 87, 147, 148, 184, 218, 287
 effects 17, 23, 87, 218, 287
 metabolites 13, 147, 218
 properties 184
 sterols 148
Cytotoxic activity 21, 23, 86, 174, 178, 179, 184, 195, 197, 202, 204, 221, 222, 269, 275
 displayed light-based 86
 promising 178

D

Dalton's lymphoma ascites tumour (DLAT) 199
Deaths 2, 9, 235
 inducing apoptotic 9
Digestive gland 239, 243
Display 16, 17, 96, 176, 218, 224, 227, 232, 283, 308, 323, 325
 anti-tumor activity 283
 anticancer 232
 anticancer effects 96
 anti-tumor activity 17
 cytotoxic effects 218
 cytotoxicity 16, 176, 224, 323, 325
 inhibitory activity 227, 308
Displayed 49, 50, 51, 72, 73, 74, 78, 88, 91, 94, 95, 97, 98, 101, 102, 106, 110, 111, 114, 115, 130, 138, 141, 147, 173, 177, 184, 200, 264, 266, 270, 274, 299, 308, 311, 333
 anticancer activity 49, 50, 51, 72, 88, 97, 98, 110, 115
 anticancer effects 72, 73, 74, 78, 91, 94, 95, 98, 102, 141, 173
 cytotoxic activity 95, 101, 106, 111, 130, 138, 141, 177, 184, 264, 270
 potent cytotoxicity 110, 114, 147, 200, 266, 274, 299, 308, 311
 potent cytotoxicity inhibition 333
DNA 34, 177
 fragmentation 177
 synthesis and protein synthesis inhibitor 34

Medicinal Chemistry and Marine Life, Vol. 1 359

DNA topoisomerase 33, 230
 inhibitor 33
Dolastatin 17, 18, 67
 linear peptide 67
 peptide derivatives 18
Doxorubicin, liposomal 17
Drug(s) 2, 3, 6, 7, 23, 29, 30, 44, 61, 80, 82, 99
 anti cancer 61
 antipsychotic 82
 industries 7

E

Effects 51, 82, 125, 210
 antiproliferating 51
 cytolytic 210
 induced apoptotic 125
 therapeutic 82
Ehrlich ascites 190, 199
 carcinoma (EAC) 199
 leukemia 190
Ehrlich carcinoma cells 274, 330
Endothelial cell apoptosis 338
Enzymes, metabolic 17
Epidermal 294, 315
 cancer 294
 carcinoma 315
Epidermoid carcinoma 64, 191, 218, 267, 271, 303, 314
 oral 191
European 21, 22, 51, 65, 155
 medical agency (EMA) 21, 22, 155
 medicines evaluation agency (EMEA) 51, 65

F

Fatty acid 9, 10, 35, 46, 61, 113, 336
 monounsaturated 46
 polyunsaturated 46, 61
Fibroblasts 93, 98, 245, 259, 298
 neonatal foreskin 298
Fibrosarcoma 191
Formation 9, 16, 264, 267, 273, 275
 anti-colony 16
 inhibiting vascular endothelial growth factor 9
Fractions 74, 101, 275
 glycolipid 275

- hydrophobic 74
 - polyphenolic 101
 - Fucose-containing sulfated polysaccharides (FCSPs) 19
- G**
- Gene 17, 24, 45, 83, 84
 - expression 17
 - mining 45
 - protein coding 24
 - Glioblastoma 32, 33, 183, 210, 211, 255, 280
 - Glycoprotein 92, 140
 - Glycosphingolipids 147, 275, 296
 - Glycosylated compounds 232
 - Growth 16, 49, 177, 185, 210, 249, 338, 339
 - inhibition 49, 177, 185, 338, 339
 - inhibitory activity 16, 210, 249
- H**
- HeLa cancer 121
 - Hematological malignancies 34
 - Hepatic cancer 5
 - Hepatocellular carcinoma 72, 89, 150, 230, 271
- I**
- Inhibition 147, 277, 287
 - migration and colony 277
 - of colony formation 277
 - proliferation 147, 277, 287
 - Inhibitor 21, 33, 35, 126, 133, 333
 - phosphotransferase 35
 - tyrosine kinase 35
- J**
- Jurkat cancer cells 135, 162
- L**
- Lactones, organic 161
 - Leukemia 26, 27, 72, 73, 170, 183, 184, 187, 189, 198, 211, 218, 221, 224, 226, 228, 230, 237, 239, 242, 249, 253, 255, 257, 306, 320
 - inhibited 170
 - lymphoblastic 187
 - lymphocitic 189
 - lymphocyte 184
 - murine 198, 218, 230, 306
 - promyelocytic 72, 73, 187, 211
 - Leukemic monocyte lymphoma cell 71
 - Lipid 71
 - carbohydrate compounds 71
 - Lipid peroxidation 93, 96, 176
 - hepatic 93
 - membrane 96
 - Lipogenesis 17
 - Liver 2, 93, 211, 232, 237, 266, 339
 - adenocarcinoma 93
 - cancer 2, 232, 339
 - carcinoma 211, 237, 266
 - Lung 47, 67, 101, 184, 201, 331
 - adenocarcinoma 47, 67, 201
 - fibroblast 101, 184, 331
 - Lung cancer 2, 23, 27, 32, 64, 67, 75, 76, 91, 191, 287
 - metastatic small-cell 23, 27
 - Lung carcinoma 55, 64, 75, 105, 190, 192, 211
 - non-small cell 211
 - cells 55
 - Lymphocytes 227
 - Lymphocytic leukemia 185, 192, 194, 195, 196, 200, 208, 209, 227, 230
- M**
- Macrolide 12, 18, 26, 152, 153, 154, 155, 158, 250, 252, 256, 261, 324
 - aplyronine 250
 - glycosides 252
 - glycosylated polyketide 324
 - lactones 18
 - Malignant 2, 34, 35, 105, 262
 - melanoma 34, 35, 262
 - neoplasms 2
 - ulcers 105
 - Mammary adenocarcinoma 63
 - Marine 1, 7, 9, 10, 12, 19, 20, 24, 30, 32, 33, 44, 46, 112, 172, 237, 260
 - actinomycete 33
 - anticancer drugs 20
 - cyanobacteria 24, 30
 - drug discovery 7

Subject Index

ecosystems 1, 9, 10, 19, 44
environment 1, 44, 172
fungus 32
gastropods 12, 237, 260
macroalgae 9
microalgae 9, 46, 112
phytoplankton 112
Melanoma 64, 75, 94, 95, 97, 109, 111, 183,
189, 190, 192, 194, 223, 224, 227, 230,
267, 271
cancer cells 64
cells 75, 94, 109, 111
leukemia 223
Metabolites 11, 12, 200, 216, 231, 262, 264,
322, 340
anti-proliferative 231
Metastasis 3, 95, 151
Metastatic 155, 274
breast cancer patients 155
melanoma 274
Microcystins 53, 54
Microtubule 27, 161
-associated inhibitors 27
inhibitor 161
Mitochondrial dysfunction pathways 101
Mitosis 33, 34, 35, 36, 71, 131
inhibitor 33
Mitotic 16, 84
divisions 16
separation 84
Multiple myeloma 27, 32, 33, 34, 96, 335
Murine 79, 80, 227, 230, 270, 322, 326
leukaemia 322
lymphoma 80
melanoma 79, 227, 230
sarcoma 326
splenocytes 270
tumor 230
Myelodysplastic syndromes 35

N

Natural disasters 10
Necrosis 99, 176, 261
muscle 176
Neuroblastoma 67, 226
Neurodegenerative diseases 82
Neurotoxin 12
Nuclear 233
augmentation 233

Medicinal Chemistry and Marine Life, Vol. 1 361

condensation 233
Nucleosides 10, 26, 113, 170

O

Organic polymer 159
Ovarian cancer 2, 17, 26, 135, 209
relapsed 17

P

Pancreatic cancer 2, 34
Peptide(s) 51, 65, 232, 249
drug 51, 65
fractions 232
macrocyclic 249
Peptidoglycans 261, 262
Pheochromocytoma 157
Pipeline process 2
Plants, marine medicinal 46
Plomyelocytic leukemia 218
Polyacanthoside 267, 268, 276
Polyhydroxylated steroids 276
Polyhydroxysteroidal glycosides 264, 275,
276
Polyhydroxysteroids 277
Polyketide metabolites 9
Polyoxygenated steroids 214, 215
Polypeptides 173, 175
Polysaccharides 9, 15, 16, 18, 19, 46, 48, 95,
97, 262, 277, 281, 283
Properties 13, 44, 232
anti-osteoclastogenic 232
cancerostatic 13
Prostate carcinoma 187
Proteasome system 133

Protein(s) 9, 11, 17, 33, 34, 35, 59, 61, 126,
131, 140, 145, 172, 227, 275, 297, 340
hydrolysates 297, 340
kinase 9, 17, 33, 126, 227
kinesin-binding 131
recombinant water stress 59
secretion 17
synthesis inhibitor 34
water stress 59
Purine arabino-nucleoside 18

S

Saponins 13, 102, 189, 232, 269, 271, 281, 287, 289, 293, 296
Sarcoma 97, 105, 293
Secondary metabolites 1, 5, 8, 10, 12, 13, 15, 112, 113, 340
Sessile invertebrates 10
Shrimp wastes 232
Singlet oxygen 280
Skin 75, 78, 209, 269, 339
 cancer 75, 209, 269
 gelatin 339
 melanoma cells 78
Soft tissue sarcoma 26, 117
Solid tumors 3, 21, 27, 33, 34, 35, 93
Sphingolipid 237
Squamous cell carcinoma (SCC) 200, 211, 241
Steroid 232, 275, 276
 biglycosides 275
 glycoside 232, 276
Steroidal 194, 263, 276, 277
 carboxylic acids 194
 compounds 263
 glycosides 276, 277
Steroids 13, 98, 144, 148, 151, 192, 195, 214, 232, 234, 237, 267, 269
 containing 98, 195
 polar 269
Sterol compounds 197
Suppression, potent tumor cell growth 284
Survival, cancer cell 175
Synthesis 9, 44, 111, 169
 enzymatic 44

T

Taxonomic problems 217
Toxicity, delaying neuromuscular 17
Toxins 11, 84, 85, 90, 156, 210
 hemolytic 11
 pore-forming cytolytic 210
Transcription factor inhibitor 34
Tryptophan glycoconjugate 319
Tubulin polymerization inhibitor 33, 34, 35, 36
Tumor 2, 3, 34, 83, 94, 96, 97, 119, 145, 161, 283, 315
 carcinoma 315

 development 97
 gene-deficient 83
 hematopoietic 161
 inhibitor 283
 progression 119
 suppressor 145
Tumor cell 94, 108, 124
 glutathione 108
 migration 94
 senescence 124
Tumor growth 50, 223, 287
 inhibition 223
Tumorigenicity 96

V

Vascular endothelial growth factor 292
Venom protein 176

W

Waste bioremediation 14



Ramasamy Santhanam

Prof. Ramasamy Santhanam is the former dean of the Fisheries College and Research Institute (FC & RI, presently under Tamil Nadu Dr. J. Jayalalithaa Fisheries University), Tamil Nadu Veterinary and Animal Sciences University, Thoothukudi, India. He has served as a resource person for several training workshops in India and abroad and participated and presented research papers at 13 International Fisheries Science Conferences held in Canada, Panama, Denmark, Germany, Spain, The Netherlands, Switzerland, Japan, S. Korea, and Australia. He served as a member of the American Fisheries Society, United States; World Aquaculture Society, United States; Global Fisheries Ecosystem Management Network (GFEMN), United States; and the IUCN's Commission on Ecosystem Management, Switzerland. Presently he is on the editorial board member of the Mediterranean Aquaculture Journal. He has 37 books published on various aspects of marine biology/fisheries science viz. marine life, fisheries biology, aquaculture and fisheries environment. Three of his books have been listed as "Best Marine Biology Books of All Time" by the World Book Authority.



Santhanam Ramesh

Prof. Santhanam Ramesh is serving as vice principal, at Karuna College of Pharmacy, Kerala University of Health Sciences, Palakkad, Kerala, India. He has 12 years of teaching and research experience. He was a visiting professor at the Medical Institute of the North-Caucasian State Humanitarian and Technological Academy (The state university), Cherkessk, Karachay-Cherkessia, Russia. He is a member of different societies such as the Academic Pharmacy Group of the Royal Pharmaceutical Society, London, International Society for Pharmacoeconomics and Outcome Research (ISPOR), USA; etc. He has 11 books and 20 research papers to his credit.



Subbiah Balasundari

Prof. Subbiah Balasundari is the dean-in-charge at Dr. M.G.R. Fisheries College and Research Institute at the TamilNadu Dr. J. Jayalalithaa Fisheries University, Thalainayeru, India. She has 25 years of teaching and research experience in fish processing. She has developed a number of contemporary value-added fish products and has disseminated the technologies to the fish processing industries of India. She has completed six projects through funding agencies at national level and has established various demonstration units in fisheries enterprises for the benefit of stakeholders. She is a member of the World Aquaculture Society, Asian Fisheries Society (Indian Branch), Agricultural Scientific Tamil Society, and Society of Fisheries Technologists.



Sheba David

Sheba David, PhD, is serving presently as an Assistant Professor, Pharmaceutical Sciences in the University of Wyoming, USA. She graduated her B Pharm from Dr. MGR Medical university, Chennai, India. She obtained her Master in Biomedical Engineering (with University Gold Medal) and PhD degree from Jadavpur University, Kolkata, India. She was also a Postdoctoral Scientist in the Department of Pharmaceutical Sciences, University of Geneva, Switzerland. She possesses about 15 years of teaching and research experience which was with International Medical University, Kuala Lumpur, Malaysia; and PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei. Her research specializations include natural products, drug delivery and pharmacology. To her credit, Dr. David has about 50 research papers published in peer-reviewed journals and 4 books published with internationally reputed publishers viz. CRC Press (Taylor & Francis) USA, Cambridge Scholars Publishing, UK and John Wiley & Sons.